Oncology Books

2618 products


  • Oral and Oropharyngeal Cancer

    Taylor & Francis Inc Oral and Oropharyngeal Cancer

    15 in stock

    Book SynopsisThe prevalence of Oral and Oropharyngeal Cancer continues to rise worldwide, related to the increase in consumption of tobacco, alcohol and other carcinogenic products. However, there has also been a significant reduction in mortality due to increasing awareness, early diagnosis and advances in treatments. This second edition of a bestseller reviews every aspect of the diagnosis and treatment of the orofacial cancer patient. As with the first edition, the book is organized in three parts, covering Pathology and Biology, Clinical Management, and Outcomes and Follow-up.Trade ReviewThe production is of an excellent quality. The book contains many clinical, surgical, and histopathological coloured figures, graphs, tables which enhance the information and readability of each chapter. This book remains timely and appropriate for all clinicians, surgical and non-surgical, clearly documenting the state of the art of modern-day diagnosis, treatment and management of patients who present with an oral and/or oropharyngeal cancer. This volume should be available for referencing in all cancer centres, which undertake treatment of patients presenting with head and neck cancer.Professor Patrick J Bradley, MBA FRCS, Emeritus Honorary Professor of Head and Neck Oncologic Surgery The University of Nottingham, UK, The Journal of Laryngology & OtologyTable of ContentsPart I: Pathology and Biology. Global epidemiology. Etiology and risk factors. Clinical features and diagnosis. Histopathology. Molecular pathology. Part II Clinical Management. Clinical evaluation and differential diagnosis. Workup and Staging. Factors affecting choice of treatment. Management of potentially malignant disorders of the mouth and oropharynx. Cervical lymph nodes. Surgical approached to oral cavity and oropharynx. Radiotherapy. Chemotherapy. Complications of treatment and their management. Reconstructive Surgery: Soft tissue. Reconstructive Surgery: Mandible. Reconstructive Surgery: Maxilla. Palliative care for head and neck cancer. Part III Outcomes and Follow-up. Oncologic Outcomes. Functional outcomes and rehabilitation. Prognostic Nomograms. Prosthetic restoration and rehabilitation. Prevention.

    15 in stock

    £210.00

  • Surgical Oncology

    Taylor & Francis Inc Surgical Oncology

    Out of stock

    Book SynopsisSurgical oncology is now a recognized specialty in the US and several European countries, and cancer surgery takes up a significant part of any general surgeon's workload. This thoroughly updated second edition of this bestseller is officially endorsed as a textbook for the syllabus and curriculum of the UEMS examination in Surgical Oncology, which is administered by ESSO (European Society for Surgical Oncology). The examination is for trainees at the end of training or established consultants seeking to expand their accreditation. Table of ContentsCancer epidemiology. Genetics and hereditary cancer syndromes, genetic polymorphisms and cancer. Clinical trial design in surgical oncology. A critical overview of screening for cancer. Principles of radiation therapy for surgeons. Intraoperative radiotherapy. Principles of systemic therapy for surgeons. Quality assurance in surgical oncology. Palliative care in surgical oncology. Communication and psychological needs of the cancer surgery patient. Nutrition in cancer and cancer surgery. Image-guided surgery. The role of interventional radiology in the management of cancer patients. Minimal access and robotic surgery. Surgery for older cancer patients. Cancer of unknown primary. Oral cancer. Salivary gland tumors. Paranasal sinus cancers. Skull base tumours. Cancer of larynx and hypopharynx. Breast cancer. Lung and pleura. Esophageal cancer. Gastric cancer. Gastrointestinal stromal tumor. Small bowel and appendiceal tumors. Cancer of the colon and rectum. Anal cancer. Peritoneal surface malignancy. Pancreatic and ampullary cancer. Hepatocellular carcinoma. Carcinoma of the biliary tree and gallbladder. Liver metastases. Renal cell carcinoma. Urothelial carcinoma of the bladder and upper tract. Prostate cancer. Testicular tumours. Gynaecological oncology. Skin cancer: Squamous cell carcinoma and basal cell carcinoma. Skin: Melanoma. Thyroid cancer. Adrenal tumours. Parathyroid cancer. Neuroendocrine tumours of the gastrointestinal tract. Bone sarcoma. Extremity soft tissue sarcoma. Retroperitoneal sarcoma. Neurosurgical oncology: Neoplasms of the brain and meninges.

    Out of stock

    £999.99

  • Hyperthermia in Oncology

    Taylor & Francis Inc Hyperthermia in Oncology

    Out of stock

    Book SynopsisHyperthermia in oncology is the application of heat to a patient's body for the purpose of cancer treatment. In recent years, its use has seen rapid development, with a large amount of clinical data becoming available. Hyperthermia in Oncology synthesizes the current research on the topic and provides treatment protocols for using localized as well as whole-body hyperthermia. The differentiating characteristic of this book is the systematic documentation of evidence. Standard procedures for cancer diagnosis, treatment, and management are included along with guidance for evaluating clinical therapeutic effects. The book examines the unique effects of hyperthermia treatment with a large quantity of evidence-based data from both medical research and clinical practice. It reviews outcomes of cancer patients clinically treated at Clifford Hospital, a state-of-the-art facility with Joint Commission International accreditation located in Guangzhou, China.Table of ContentsIntroduction. Overview of Hyperthermia in Oncology. Categories and Methods of Hyperthermia in Oncology. Physical Technology and Biological Basis of Hyperthermia in Oncology. Hyperthermia in Oncology and Nontoxic Integrative Treatments. Clinical Applications of Hyperthermia in Cancer Treatments. Integrative Hyperthermia Treatments for Different Types of Cancer. Nursing Care Techniques on Hyperthermia in Cancer Treatment. Therapeutic Protocols of Integrated Hyperthermia Treatment for Noncancerous Diseases. Bibliography. Appendices.

    Out of stock

    £999.99

  • Complementary and Alternative Medicines in

    Taylor & Francis Inc Complementary and Alternative Medicines in

    1 in stock

    Book SynopsisRecent global cancer statistical data has clearly indicated that prostate cancer is currently the second most frequently diagnosed cancer (at 15% of all male cancers) and globally the sixth leading cause of cancer death in males. This book is a summary of prostate cancer, covering its incidence, epidemiology, and current treatment options. It also serves as an up-to-date review of the status of currently available alternative and complementary medicines for treating prostate cancer, including various plant extracts, herbal formulations, natural products, yoga, acupuncture, Ayurveda, homeopathy, and Siddha medicines used in prostate cancer therapy.Trade Review"Exceptionally well organized and presented, "Complementary and Alternative Medicines in Prostate Cancer" is unreservedly recommended as a core addition to college and university library Health/Medicine collections in general, and Prostate Cancer supplemental studies reading lists in particular."-- James A. Cox, Editor-in-Chief, Midwest Book ReviewTable of ContentsProstate cancer: an introduction. Prostate cancer epidemiology. Molecular biology of prostate cancer. Current treatments and reasons for treatment failure. Preclinical status of novel approaches for prostate cancer therapy. Triterpenoids and sesquiterpenes. Curcumin. Resveratrol.Complementary and Alternative Medicines in Prostate Cancer: From Bench to Bedside. Phyllanthus sp: Bitter melon extract. Kava. Plumbagin. Urokinase inhibitors from plants. Chinese Herbal among Prostate Cancer Patients: A Population-Based Study in Taiwan. lternol.Betel leaf.Spice derived anticancer molecules for prostate cancer. Nutraceuticals and prostate cancer. Isoflavinoids. Pomegranate. Green tea. Broccoli. Pomi-T supplements. Other forms of CAM. Yoga and prostate cancer. Acupuncture. Homeopathy. Siddha medicines.

    1 in stock

    £175.00

  • Oncoplastic and Reconstructive Management of the

    Taylor & Francis Inc Oncoplastic and Reconstructive Management of the

    15 in stock

    Book SynopsisOncoplastic and Reconstructive Management of the Breast, Third Edition provides a comprehensive and contemporary account of techniques in oncoplastic and reconstructive breast surgery. Uniquely, this book includes short, concise chapters containing only the most critical information. Many of the chapters are entitled My Approach and this enables the reader to gain an insight into the clinical practice of the world''s breast disease experts. The true multidisciplinary nature of the book ensures that the perspectives of all members of the breast cancer team are included. This transfer of knowledge between disciplines leads to improved patient care and the integration of multidisciplinary treatment, thus providing an educational and practical multidisciplinary breast cancer book for practicing breast cancer doctors, and trainees worldwide.Table of ContentsSection I: General trends, principles, and materials. 1. Latest trends in breast reconstruction. 2. The biological rationale for oncoplastic surgical procedures. 3. Biological reactions to reconstructive materials. Editorial Commentary. Section II: Patient selection - breast-conserving surgery or mastectomy? 4.Oncological considerations. 5. Reconstructive perspectives. 6. Patients’ perspectives. Editorial Commentary. 7. Preoperative radiological assessment. 8. Oncoplastic parenchymal resection. 9. Intraoperative assessment. 10. Timing of oncoplastic repair. Editorial Commentary. Section III: Breast-conserving surgery and partial breast reconstruction (oncoplastic repair). 11. Immediate repair before radiotherapy. 12. Postoperative margin assessment (re-excision or completion mastectomy). 13. Delayed oncoplastic repair - before radiotherapy. Editorial Commentary. 14. Delayed oncoplastic repair - after radiotherapy. Editorial Commentary. Section IV: Skin-sparing and nipple-sparing mastectomy. 15. Mastectomy and whole breast reconstruction: skin-sparing and nipple-sparing mastectomy. Editorial Commentary. 16. Nipple-sparing mastectomy. Editorial Commentary. Section V: Mastectomy and whole breast reconstruction (timing and patient selection). 17. Timing of reconstruction. Editorial Commentary. 18. How to choose the optimal method of whole breast reconstruction. Section VI: Mastectomy and whole breast reconstruction (methods and techniques). 19. Implant-based whole breast reconstruction (without irradiation). Editorial Commentary. 20. Implant-based whole breast reconstruction (with irradiation). 21. Fat grafting exclusively for whole breast reconstruction. Editorial Commentary 22. Standard autologous tissue flaps for whole breast reconstruction. Editorial Commentary. 23. Advanced autologous tissue flaps for whole breast reconstruction. Section VII: Revisional breast reconstruction (following both partial and whole breast reconstruction). 24. Breast revision following breast conservation and oncoplastic repair. 25. Breast revision after implant-based breast reconstruction. 26. Breast revision after mastectomy, whole breast reconstruction, and postmastectomy radiation therapy. Editorial Commentary. Section VIII: Techniques for delivery of radiotherapy. 27. Partial or whole breast radiotherapy after breast-conserving surgery. 28. Postmastectomy radiotherapy after whole breast reconstruction. 29. Partial breast radiotherapy after partial mastectomy. 30. Whole breast radiotherapy (BOOST) after partial mastectomy. Editorial Commentary. Section IX: Techniques for lymph node transfer. 31. Transfer of lymph node tissue. Section X: Nipple-areola complex reconstruction. 32. Nipple-areola complex reconstruction (with and without Biologicals. Editorial Commentary. Section XI: Training - breast surgery as a specialty. 33. The modern specialist breast surgeon. 34. Breast surgical training. Editorial Commentary.

    15 in stock

    £150.00

  • Cancer Crossings

    Cornell University Press Cancer Crossings

    10 in stock

    Book SynopsisWhen Eric Wendel was diagnosed with acute lymphoblastic leukemia in 1966, the survival rate was 10 percent. Today, it is 90 percent. Even as politicians call for a Cancer Moonshot, this accomplishment remains a pinnacle in cancer research.The author's daughter, then a medical student at Georgetown Medical School, told her father about this amazing success story. Tim Wendel soon discovered that many of the doctors at the forefront of this effort cared for his brother at Roswell Park in Buffalo, New York. Wendel went in search of this extraordinary group, interviewing Lucius Sinks, James Holland, Donald Pinkel, and others in the field. If there were a Mount Rushmore for cancer research, they would be on it.Despite being ostracized by their medical peers, these doctors developed modern-day chemotherapy practices and invented the blood centrifuge machine, helping thousands of children live longer lives. Part family memoir and part medical narrative, Cancer CrossingsTrade ReviewBoth informative and compassionate, Wendel's book celebrates his brother's life and serves as a testament to the commitment of doctors who went above and beyond expectations to transform a death sentence into a survivable disease. A sensitive and thoughtful excavation of a painful period in the author's life. * Kirkus Reviews *Responds brilliantly to Sontag’s decades-old call for new metaphors, new ways of imagining cancer.... Wendel approaches an emotional and highly fraught topic with gentleness and compassion for the reader. * Washington Independent Review of Books *This fine book combines dual pleasures for readers: it's a heartfelt excavation of a painful stretch in the author's life and a history of a seminal period in oncology.... This compelling book is highly recommended for readers of The ASCO Post. * The ASCO Post *

    10 in stock

    £18.99

  • Basic Books The First Cell: And the Human Costs of Pursuing

    Out of stock

    Book SynopsisIn The First Cell, Azra Raza offers a searing account of how both medicine and our society (mis)treats cancer, how we can do better, and why we must. A lyrical journey from hope to despair and back again, The First Cellexplores cancer from every angle: medical, scientific, cultural, and personal. Indeed, Raza describes how she bore the terrible burden of being her own husband's oncologist as he succumbed to leukemia. Like When Breath Becomes Air, The First Cell is no ordinary book of medicine, but a book of wisdom and grace by an author who has devoted her life to making the unbearable easier to bear.

    Out of stock

    £20.69

  • In My Hands: Compelling Stories from a Surgeon

    Little, Brown & Company In My Hands: Compelling Stories from a Surgeon

    5 in stock

    Book SynopsisIn IN MY HANDS, surgical oncologist Dr. Steven Curley shares the empowering lessons he's learned over 25 years from his cancer patients' unique stories of struggle, perseverance, and triumph.As Chief of Surgical Oncology at Baylor College of Medicine, Dr. Steven Curley has worked with cancer patients for over two decades. While his life's work has been to help his patients live longer lives, he found that they helped him in ways he never could have expected.IN MY HANDS is a rare, often emotional look at some of Dr. Curley's real patients and real situations in modern cancer care. These stories of resilience, hope, and determination changed and inspired Dr. Curley, and he uses these same stories to encourage patients dealing with the fear and uncertainty coupled with a diagnosis of cancer.Every story in the book has a theme inspired by his patients: Hope, Courage, Strength, Determination, Wonder, Cooperation, Creativity, Diligence, Service, Perseverance, Wisdom, Grace, Consideration, Gratitude, Discernment, Reverence, Resourcefulness, Faith, Beauty, Acceptance, and Empathy. Some are positive messages, reminding us of the importance of maintaining balance between family, work, and leisure activities. Others are examples of the remarkable resilience of the human spirit when facing the reality of and the surgical risks that accompany a cancer diagnosis. Realistically, despite remarkable advances in multidisciplinary cancer care, some remind us cancer is still a potentially lethal and destructive disease affecting patients and the family and friends supporting them.While many people are told that there is no hope in their situation, Dr. Curley's patients taught him to always provide hope, to push the envelope and give people a chance, and that hope is a critical component of treatment and care. IN MY HANDS is medical narrative at its finest, and provides insight into medicine and patient care along with fascinating details about one of our most feared diseases.

    5 in stock

    £19.80

  • Living With Childhood Cancer: A Practical Guide

    American Psychological Association Living With Childhood Cancer: A Practical Guide

    1 in stock

    Book SynopsisLike a natural disaster, the diagnosis that your child has cancer can leave you and your family feeling helpless. How do you explain the disease to the child and to his or her siblings? How can you communicate your child's needs to the hospital staff? What are the best ways to reduce the physical side effects and the emotional distress of treatment?How will you, your child or teenager, and the rest of your family cope with cancer, and what can you do to help? When and where do you find good psychological help for your child or your family? How do you manage financial and school issues? How can you foster your child's development and self-esteem? More than 12,000 American children will be diagnosed with cancer this year, and roughly 75% will survive. In addition to excellent medical care, their survival depends on a strong support network, which may include parents, siblings, extended family members, friends and neighbors, classmates and teachers. In this down-to-earth guidebook, the authors draw on their own family's experience with cancer as well as their professional expertise and stories from others to help families address the psychological impact of cancer. The result is a book filled with sound emotional guidance, useful information, and practical advice for families coping with cancer. Trade ReviewThis book is an excellent roadmap for families who are faced with the shattering experience of having a child with cancer. * University of Pennsylvania School of Medicine *Noting individual differences in styles and preferences, the authors provide a detailed listing of ways for parents to help themselves and their children emotionally. These are concrete actions and strategies based on the experiences of those who have tried to adapt successfully to the diagnosis and treatment of a child with cancer…The book is recommended as a valuable resource for families, professionals and others who want to learn about coping with pediatric cancer. * Journal of Pediatric Hematology/Oncology *Table of ContentsAcknowledgments Introduction Chapter 1: Navigating the Emotional Terrain Chapter 2: Creating and Working With the Team: Doctors, Nurses, Health Insurers, Teachers, and Others Chapter 3: Coping Successfully Chapter 4: Understanding the Impact on Your Family and Friends Chapter 5: Handling Emotions and Communicating Well Chapter 6: Reducing Stress Chapter 7: Alleviating Trauma Chapter 8: Recognizing Special Risks for Stress and Trauma Chapter 9: Relieving Pain and Side Effects Chapter 10: Encouraging Child Development Chapter 11: Building Self-Esteem in Your Child Chapter 12: Dying and Grieving Chapter 13: Surviving and Carrying the Torch Bibliography Resources Author Index Subject Index About the Authors

    1 in stock

    £16.19

  • Cutaneous Melanoma, Fifth Edition

    Taylor & Francis Inc Cutaneous Melanoma, Fifth Edition

    1 in stock

    Book SynopsisThe Classic Text—Expanded, Updated...More Authoritative than Ever!Cutaneous Melanoma is the definitive and most authoritative textbook on melanoma used worldwide. This 5th edition provides the most up-to-date and comprehensive information needed for the clinical management and scientific study of melanoma. Written by the leading melanoma experts from the United States, Australia, and Europe, this new edition collectively incorporates the clinical outcomes of more than 60,000 patients treated at major melanoma centers throughout the world.Comprehensive Coverage—from Prevention to Advanced TreatmentThis new edition provides in-depth coverage, ranging from precursors of melanoma to advanced stages of metastatic disease; from melanoma genes to population-based epidemiology; and from prevention of melanoma to all forms of multidisciplinary treatments. Basic principles of diagnosis and pathologic examination are combined with treatment approaches for the many clinical presentations. Clinical management is supported by statistical data about natural history, prognosis, and treatment results. The latest information on staging and prognosis, as well as randomized prospective clinical trials involving surgical treatment and systemic treatments, is included. This volume presents a balanced perspective of the risks and benefits involved in each treatment modality. The book also contains: 1) a comprehensive color atlas of melanoma and its precursors, 2) illustrated surgical and perfusion techniques for every stage and anatomic location of melanoma, and 3) complex genetic and molecular pathways involving melanoma biology. Every drug and biologic agent in use today is described with indications and efficacy.Entirely Revised and UpdatedSeven new chapters discuss the emerging clinical data on the use of biomarkers, adjuvant therapies, targeted therapies, and immune modulation as well as significant clinical research advances in the clinical management of melanoma. The remaining 37 chapters have been extensively updated and revised to include the latest clinical, radiological, and pathological data and clinical trial advances.Cutaneous Melanoma, 5th Edition, retains the logical organization and clarity of expression responsible for its enduring popularity over the last 23 years. This volume will become an invaluable part of your library and a trusted resource that you will refer to again and again.The most comprehensive reference on melanoma available today! New Chapters Include: Clinical Genetics and Risk Assessment Sentinel Lymph Node and Regional Micrometastases Multidisciplinary Management of CNS Metastases Adjuvant Therapy for Cutaneous Melanoma Immune Modulation Therapy Using Anti-CTLA-4 Monoclonal Antibodies Melanoma-Specific Targeted Therapies Biomarkers for Cutaneous Melanoma Trade Review"This is the fourth edition of the book that is no doubt the premier text on cutaneous melanoma. The book is oriented to all health care workers and researchers involved in the care of patients with melanomas. This includes, but is not limited to, the dermatologist, medical oncologist, surgical oncologist, radiation oncologist, and cosmetic surgeons, as well as nurses and other practitioners who diagnose or treat patients with melanoma. The 73 distinguished contributors have combined to put together 39 chapters in 7 parts or sections. ...The photos are outstanding and the information invaluable. The book belongs in every physician’s library, whatever his or her specialty, to raise awareness of the deadly disease."—The American Journal of Cosmetic Surgery"Overall, the text is easy to use and well indexed. I find that it is my reference text of choice for any melanoma-related questions that arise during the day. The authors should be commended for their fine and highly accessible work."—American Society for Dermatologic Surgery"…should serve as an invaluable source of information to all clinicians involved in the care of patients with malignant melanoma and to basic scientists who want to become more familiar with various clinical aspects of the disease. I intend to keep it on my desk and refer to it in my practice." —Journal of the American Medical AssociationTable of ContentsIntroductionA History of Melanoma: From Hunter to Milton; Arthur J. Sober, Helen M. Shaw, John F. ThompsonJohn Hunter (1728-1793)René Laennec (1781-1826)William Norris (1792-1877)Oliver Pemberton (1825-1897)James Paget (1814-1899)Sir Jonathan Hutchinson (1828-1913)William Sampson Handley (1872-1962)Alexander Breslow (1928-1980)Vincent J. McGovern (1915-1983)Sophie Spitz (1910-1956)Arthur Allen (1910-1994)Wallace H. Clark, Jr. (1924-1997)Thomas B. Fitzpatrick, Jr. (1919-2003)Gerald W. Milton (1924-2007)Epidemiology, Prognosis, and StagingEpidemiology of Melanoma; Bruce K. Armstrong, Alisa M. GoldsteinWorldwide incidence and mortality patternsCorrelates of melanoma riskDemographic correlatesConstitutional correlatesEnvironmental and behavioral correlatesPresent and future trends in melanoma incidence and mortalityPrognostic Factors and Natural History of Melanoma; Jeffrey E. Gershenwald, Charles M. Balch, Seng-jaw Soong, John F. ThompsonAJCC melanoma staging system analyses—overview of the AJCC international melanoma database and 2002 melanoma staging systemBackgroundOverview of the 2002 (sixth edition) AJCC melanoma database and melanoma staging systemValidation of the AJCC melanoma staging systemPrognostic factors in primary melanoma (stages I and II)Prognostic factors in regionally metastatic melanoma: lymph node metastases, satellite lesions, and in-transit metastasesAJCC melanoma database: multivariate analysis for stage III patientsPrognostic factor analyses in patients with distant metastatic melanoma (stage IV)AJCC melanoma database analysis: stage IVMelanoma Staging and Classification; Charles M. Balch, Jeffrey E. Gershenwald, Seng-jaw Soong, Arthur J. Sober, John M. KirkwoodAnatomyPrimary sitesRegional lymph nodesMetastatic sitesRules for classificationClinical stagingPathologic stagingClinical versus pathologic stagingTNM classificationPrimary tumor (T)Regional lymph nodes (N)Distant metastatic melanoma (M)Staging recommendations for metastases from unknown primary siteStage groupingsData-recording criteriaModels for Predicting Melanoma Outcome; Seng-jaw Soong, Shouluan Ding, Daniel G. Coit, Charles M. BalchDescription of the statistical modelHazard functionSurvival functionPredicting outcome from initial diagnosis for patients with localized melanomaHazard function estimation and parametric modeling for localized melanomaPredicting outcome from initial diagnosis for patients with regional melanomaPredicting outcome after a disease-free interval in patients with localized melanomaClinical applicationsClinical scoring systemDisease management decisionsPatient risk classificationPlanning clinical trialsAnalysis of clinical studiesOther applicationsScreening: Clinical Assessment and PathologyMelanoma Prevention and Screening; J. Mark Elwood, Jennifer Kay Makin, Craig A. Sinclair, Robert BurtonPrevention of melanomaReducing personal exposure: shade, clothing, and sunscreensIntervention trials of the prevention of skin cancers and related lesionsBehavioral change programs for reducing personal exposureVitamin DControlling exposure to sunbedsPrevention of melanoma: recommendationsScreening for melanomaUncertainties and conflicts in melanoma screeningEvidence relating to the effectiveness of screeningPrograms of screeningChallenges in the detection of progressive melanomaClinical Genetics and Risk Assessment of Melanoma; Graham J. Mann, Hensin TsaoClinical risk assessmentBaseline risks attributable to age and sexPrevious melanoma or other skin cancerMultiple melanocytic neviSkin and hair color, skin phototype, and frecklingSun exposure and its surrogatesFamily history of melanomaGenetic risk of melanomaMutations in CDKN2A and CDK4 in familial melanomaPancreatic cancer and other phenotypesCDKN2A mutations in sporadic and multiple primary melanomaMelanoma risk to CDKN2A mutation carriersLow-penetrance melanoma susceptibility genesGenetic testing for melanoma risk?Management of high-risk individualsThe futureAcquired Precursor Lesions and Phenotypic Markers of Increased Risk for Cutaneous Melanoma; Scott W. Menzies, Hensin Tsao, Arthur J. SoberPigment phenotypeConstitutive pigmentation (racial)Hair and eye colorOculocutaneous albinismEphelis (freckle)MolesBenign (common) acquired moles (nevi)Atypical molesLentigo malignaClinical Characteristics of Melanoma; Allan C. Halpern, Ashfaq A. Marghoob, Arthur J. SoberPersonal history of skin cancerClinical presentationSigns and symptomsClinical featuresGrowth patternsClinical assessmentHistoryPhysical examinationsDiagnostic accuracy and aids to diagnosisNew technologies for diagnosisImage analysis for diagnosisMultispectral imaging and automated diagnosisConfocal scanning laser microscopyOther techniques: ultrasound imaging, magnetic resonance imaging, and optical coherence tomographyEvolving paradigms in the analysis of dermoscopic imagesHow we analyze imagesBiopsy of Suspected Melanomas; Nanette J. Liégeois,Timothy M. Johnson, Arthur J. SoberPrebiopsy lesion assessmentBiopsy techniquesExcisional biopsyIncisional biopsyFine-needle aspirationFrozen sectionsBiopsy of the nail unitBiopsy of the mucosaPathology of Melanoma; Richard Anthony Scolyer, Martin C. Mihm, Jr., Alistair J. Cochran, Klaus J. Busam, Stanley William McCarthyPathologic assessment of melanocytic tumors: goals and expectationsBiopsy techniques for clinically suspicious melanocytic tumors: the hazards of incomplete biopsiesPathologic examination of the primary melanoma siteClinical correlation for enhancement of pathologic accuracySpecimen orientationMelanoma tumor progression: the concept of radial and vertical growth phasesClinicopathologic classification of melanomaSuperficial spreading melanomaLentigo maligna melanomaAcrolentiginous melanomaNodular melanomaHistologic features of vertical growth phase melanomaPredominantly epithelioid cell vertical growth phasePredominantly spindle cell vertical growth phasePitfallsMixed spindle cell and epithelioid cell vertical growth phaseNevoid vertical growth phase (nevoid melanoma)PrognosticationThe melanoma pathology report including a synoptic formatUncommon melanoma variantsMetastatic melanomaFine-needle biopsy in melanoma patientsClear cell sarcoma (melanoma of soft parts)Molecular pathology of melanomaThe concept of the cancer stem cellThe metastatic niche conceptManagement of Localized MelanomaExcision of Primary Melanoma; Merrick I. RossExcision of primary melanoma: fundamental conceptsHistorical perspective and the emergence of a contemporary paradigmThin melanoma (T1 and T2; less than 2 mm) excision trialsThe Intergroup Melanoma Surgical Trial (T2 and T3 melanomas; 1 to 4 mm)Thicker melanoma (T3 and T4; greater than 2 mm) excision trialsCurrent recommendationsExcisions for histologic variantsTechniques for routine wound closureExcisions for melanomas in unusual or restrictive locationsComplex Closures of Melanoma Excisions; Maurice Y. Nahabedian, Jonathan R. Stretch, Anthony P.TufaroPrinciples of reconstructive surgeryAssessment of the acquired defectReconstructive options for complex woundsDefinitionsUndermining with primary closureSkin graftsComposite graftsLocal flapsRegional flapsFree tissue transferTissue expansionComplex closures: regional considerations and clinical applicationHead and neckTrunkExtremitiesSurgical salvage for extensive and recurrent melanomaLocal Recurrences of Melanoma and Their Management; Kenneth K.Tanabe, Douglas S. Reintgen, Charles M. BalchDefinitionMechanismsRisk factors for local recurrenceSurgical margins and local recurrenceSentinel node biopsy and local recurrenceTiming of local recurrencesLocal recurrence and survivalManagementMucosal Melanoma; Merrick I. Ross, Michael A. HendersonEpidemiologyPathologic features and diagnosisStaging and prognosisMucosal melanomas in the head and neckEpidemiologyClinical presentationDifferential diagnosisPrognosis and natural historyTreatmentMucosal melanomas in the female genital tractVulvar melanomaVaginal melanomaTreatmentAnorectal mucosal melanomasClinical and pathologic featuresTreatmentMucosal melanomas at other sitesUrinary tractEsophagusRole of radiotherapyMelanoma in Children and Teenagers; Julie R. Lange, Ira J. Dunkel, Helen M. Shaw, Arthur J. SoberEpidemiologyCongenital melanomaPrecursors and risk factorsGiant congenital neviSmall and medium congenital neviXeroderma pigmentosumConstitutional risk factorsUltraviolet exposureClinical presentationDiagnosis and surgical managementMedical managementInterferonVaccine trialsChemotherapyOutcomesFollow-up and surveillancePregnancy and the Use of Hormones in Melanoma Patients; Rona M. MacKieNevi and pregnancyPregnancy before melanomaMelanoma before pregnancyMelanoma during pregnancyEffect of pregnancy on disease outcomeTransplacental metastasesTreatment of melanoma during pregnancySurgeryAdjuvant nonsurgical therapy for pregnant womenChemotherapyOral contraception and melanomaUse of oral contraception and subsequent risk of melanomaUse of oral contraceptives after treatment for melanomaHormone replacement therapy and melanomaAppropriate advice on planning pregnancy after treatment for melanomaIn vitro fertilization and melanomaManagement of Regional MetastasesThe Sentinel Lymph Node and Regional Melanoma Micrometastases; Donald L. Morton, Alistair J. Cochran, John F. Thompson, Vernon K. SondakThe history and conceptual basis of sentinel node biopsyAnatomic versus functional definitions of the sentinel lymph nodeIncubator versus marker theoryImmunology of the sentinel nodePathobiology of tumor-induced immunosuppression of the sentinel nodeSentinel node biopsy for staging clinically localized melanomaInterim results of the first Multicenter Selective Lymphadenectomy TrialSurvivalShould lymphatic mapping and sentinel node biopsy be the standard of care for cutaneous melanoma?LM/SNB increases the chance of remaining disease freeLM/SNB is a superior staging technique for identifying appropriate candidates for adjuvant therapyNo noninvasive staging alternative is availableEarly treatment of patients with a positive sentinel node may improve survival"False-positivity" does not apply to the sentinel nodeLM/SNB for melanomas that are not intermediate in thicknessUnresolved issues and ongoing researchThe second Multicenter Selective Lymphadenectomy TrialCarbon particle mappingLymphoscintigraphy in Patients with Melanoma; Roger F. Uren, John F. Thompson, Brendon J. Coventry, Barry E. ChattertonDefinition of a sentinel nodeLymphatic mapping of the skin: early studiesLymphoscintigraphyThe first radiocolloid and early experience with lymphoscintigraphyRadiopharmaceuticals99mTc-labeled colloids99mTc–antimony sulfide colloid99mTc–rhenium sulfide colloid and 99mTc-albumin nanocolloid99mTc-sulfur colloid99mTc–human serum albuminWhat is the ideal radiocolloid?Lymphoscintigraphy for sentinel lymph node biopsy proceduresLymphoscintigraphy techniqueInjecting the tracerImmediate dynamic imagingDelayed static imagingUnexpected lymphatic drainage pathwaysMarking the surface location of the sentinel nodeRadiation dosimetry: risks to the patientRadiation dosimetry: risks to the pregnant patientRadiation dosimetry: risks to attending staffPatterns of lymphatic drainage from the skinTrunkHead and neckThe limbsInterval nodesDrainage to multiple node fieldsComplex lymphatic drainage patternsLymphoscintigraphy in clinically involved node fieldsThe futureNew tracers for lymphatic mappingGamma probes for intraoperative detection of radioactivityGamma cameras for intraoperative imagingAlternate methods of lymphatic mappingIntraoperative Mapping and Sentinel Node Technology in Patients with Melanoma; Jeffrey E. Gershenwald, John F. Thompson, Nicola Mozzillo, Charles M. BalchApproach to clinically negative regional lymph node basins in patients with early-stage primary cutaneous melanomaRationale for lymphatic mapping and sentinel lymph node biopsyTechnique for lymphatic mapping and sentinel lymph node biopsyRole of sentinel lymph node biopsy in pathologic regional lymph node staging: prognostic value of sentinel lymph node pathologic statusEarly resultsPrognostic significancePatterns of failure after negative sentinel lymph node biopsyClinical relevance of submicroscopic diseaseOngoing clinical trials of lymphatic mapping and sentinel lymph node biopsyTechnical planning: overall approachPatient selectionSpecial situationsApproach to patients after previous wide local excisionApproach to patients with irregular lymphatic drainage patternsDesmoplastic histologyComplications and morbidity after lymphatic mapping and sentinel lymph node biopsyTechnical considerations: lymphatic mapping and sentinel lymph node biopsyGeneral operating room positioning strategiesAxillary and Epitrochlear Lymph Node Dissection for Melanoma; Kelly M. McMasters, Sandra L.Wong, Douglas S.Tyler, Charles M. Balch, John F. ThompsonAxillary dissectionAnatomySurgical techniqueOperative approaches to the upper axilla for recurrent or bulky axillary metastasesPostoperative managementComplicationsEpitrochlear dissectionRationaleAnatomySurgical techniqueInguinofemoral, Iliac/Obturator, and Popliteal Lymphadenectomy in Patients with Melanoma; Lisa K. Jacobs, Charles M. Balch, Daniel G. CoitInguinofemoral dissectionIndicationsTechniqueModifications of the classic technique of inguinofemoral lymphadenectomyIliac/obturator (deep pelvic) lymph node dissectionIndicationsBenefitsOperative techniquePostoperative complications: incidence and risk factorsComplications of lymph node dissectionManagement of postoperative complicationsPopliteal dissectionIndicationsOperative techniqueNeck Dissection and Parotidectomy for Melanoma; Anthony P. Tufaro, Suhail K. Mithani, Joseph A. Califano III, Ashok ShahaAnatomySublevelsPatterns of metastatic spread and extent of dissectionNeck dissectionComprehensive neck dissectionSelective neck dissectionComplicationsParotidectomyPreoperative evaluationAnesthesia and positioningTechniqueComplicationsClinical outcomeAdjuvant radiotherapyRecurrent Regional Metastases of Melanoma; Daniel G. Coit, Cristina R. FerroneIn-transit metastasesIncidenceTreatmentAdjuvant therapyPrognosisRecurrent nodal metastases after lymph node dissectionIncidenceTreatmentPrognosisAdjuvant therapyRadiotherapy for Primary and Regional Melanoma; Graham Stevens, Bryan BurmeisterRole of radiotherapy in the management of primary melanomaAdjuvant radiotherapy after surgical excisionResults of curative radiotherapy aloneRadiotherapy for lentigo maligna and lentigo maligna melanomaTreatment recommendations for the use of radiotherapy in primary melanoma and lentigo malignaIllustrative casesRole of radiotherapy in the management of in-transit metastasisTreatment recommendations for the use of radiotherapy for in-transit melanomaIllustrative casesRole of radiotherapy in the management of regional lymph node metastasisAdjuvant postoperative radiotherapy after regional lymph node dissectionResults of adjuvant radiotherapy after complete lymph node dissectionAdjuvant radiotherapy after limited lymph node dissectionPreoperative radiotherapy for bulky nodal diseasePalliative radiotherapy for unresectable regional nodal diseaseTreatment recommendations for the use of radiotherapy in regional nodal metastasisAdjuvant radiotherapy after complete lymph node dissectionAdjuvant radiotherapy after limited lymph node dissection or no dissectionTherapeutic (palliative) radiotherapyIllustrative casesHyperthermic Regional Perfusion for Melanoma of the Limbs; H. Richard Alexander, Jr., Douglas L. Fraker, Alexander M.M. EggermontEpidemiology and natural historyHistorical perspective and early clinical seriesTechnical aspects of isolated limb perfusionMelphalanPharmacokinetics of melphalan in isolated limb perfusionOther chemotherapeutic agentsHyperthermiaTumor necrosis factorToxicity of isolated limb perfusionAdjuvant isolated limb perfusionTherapeutic limb perfusionMelphalan aloneMelphalan and tumor necrosis factorIsolated Limb Infusion for Melanoma; Georgia M. Beasley, Hidde M. Kroon, Merrick I. Ross, Peter C. A. Kam, John F. Thompson, Douglas S. TylerSimilarities and differences between isolated limb infusion and conventional hyperthermic isolated limb perfusionPatient selection for isolated limb infusionTechnical details of the isolated limb infusion procedurePreoperative assessment and managementInsertion and positioning of arterial and venous cathetersProcedure in the operating roomPostoperative carePharmacokinetics of melphalanUse of microdialysis to monitor drug concentrations in limb tissues and tumor deposits during isolated limb infusionLimb and systemic toxicity after isolated limb infusionFactors predicting toxicity after isolated limb infusionClinical results of isolated limb infusionFactors predicting outcome after isolated limb infusionLimb temperatures during isolated limb infusionTourniquet timesInterpretation of prognostic factors dataRepeat isolated limb infusion for disease progression after initial isolated limb infusionComparison with hyperthermic isolated limb perfusionLaboratory studies of isolated limb infusionPotential use of the isolated limb infusion technique to evaluate other drugs and biologic agentsDiagnosis and Local Treatment of Distant MetastasesMetastatic Surveillance and Follow-up of Melanoma Patients; Julie R. Lange, Axel Hauschild, Anne Brecht FranckenGoals of surveillancePatterns of melanoma recurrenceRisk of local and regional recurrenceTime to recurrenceStrategies for active follow-up of melanoma patientsDetection of recurrencesRole of physical examinationPatient educationPatient well-being and follow-upFollow-up schedulesRadiologic studies and laboratory testsScreening for risk of new primary melanomasScreening for other primary cancersCurrent recommendations for surveillanceDiagnosis of Stage IV Melanoma; Michael B. Atkins, Axel Hauschild, Richard L.Wahl, Charles M. BalchTiming of distant metastasisPattern of metastasisPrognosis and prognostic factorsSites of distant metastasesNumber of metastatic sitesElevated serum lactate dehydrogenaseDuration of remissionPerformance statusOther prognostic factorsClinical evaluation of metastasisHistory and physical examinationLaboratory tests/biomarkersRadiologic testsPathologic testsSites of distant metastasesSkin, subcutaneous tissues, and distant lymph nodesLung, pleura, and mediastinumBrain and spinal cordGastrointestinal tractLiver, biliary tract, and spleenBoneKidneys and urinary tractHeart and pericardiumPancreasPeritoneum and mesenteryEndocrine organsBreastOvaries, uterus, and placentaTestes and penisOral cavity, pharynx, and larynxEye and orbitCutaneous melanosisMetastatic melanoma from an unknown primary siteSurveillance in patients who have localized melanomaSurgical Excision of Distant Melanoma Metastases; John F. Thompson, Donald L. Morton, Charles M. Balch, Merrick I. RossCurrent status of surgery for stage IV melanomaRelationships between tumor burden, immune function, and surgical treatmentSelection of patients and prognostic factorsOutcomes after surgical resection of melanoma metastases at specific sitesSkin, subcutaneous tissue, and lymph nodesLung, trachea, and bronchiBrain and spinal cordGastrointestinal tractLiver, biliary tract, and spleenBoneKidney and urinary tractHeart and pericardiumEndocrine organsBreastOvaries, uterus, and vaginaTestes and penisOral cavity and pharynxEye and orbitRadiotherapy for Distant Metastases and Clinical Radiobiology of Melanoma; Graham Stevens, Angela Hong, Michael J. McKayRadiotherapy for distant metastasesSkin and subcutaneous metastasesLymph node metastasesBrain metastasesMalignant spinal cord compressionBone metastasesSites irradiated less commonlyDeveloping sites for focused radiation treatmentIllustrative casesClinical radiobiology of melanomaBiologic factors affecting the ionizing radiation response of melanomaIntrinsic cellular radiosensitivityTumor oxygenation and microenvironmentalFactorsTumor cell proliferation kineticsNumber of clonogenic tumor cellsInfluence of melanization on radiosensitivityHost factors in melanoma response and outcomeFuture possibilitiesMethods to improve the response of melanoma cellsMethods to improve the delivery of radiation to melanoma metastasesMultidisciplinary Management of CNS Melanoma Metastases; Kim A. Margolin, George M. Cannon, Minesh P. Mehta, Michael Y. ChenRisk factors and prognosisClinical featuresNeurosurgical management of brain metastasisRadiotherapeutic and radiosurgical management of melanoma metastatic to the brain or spineWhole-brain radiotherapyWhole-brain radiotherapy aloneSurgery followed by whole-brain radiotherapyStereotactic radiosurgerySystemic therapy for melanoma metastatic to the central nervous systemSystemic therapy considerations after adequate control of the central nervous systemPalliative approachAggressive approachInvestigational approachSystemic Treatment of Metastatic DiseaseAdjuvant Systemic Therapy for High-Risk Melanoma Patients; John M. Kirkwood, Vernon K. Sondak, Peter Hersey, Helen GogasWho should be considered for adjuvant therapy?Chemotherapy alone or in multiagent combinations as adjuvant therapy for melanomaMicrobial immunostimulantsBacillus Calmette-GuérinCorynebacterium parvumLevamisoleHormonal therapyMelanoma vaccines tested in phase III adjuvant trialsAdjuvant interferons as postoperative adjuvant therapy for melanomaAdjuvant applications of interferon-alpha-2Adjuvant applications of interferon-gammaEmerging new modalities of adjuvant therapyBiomarkers of prognosis and responseChemotherapy-Based Treatment of Metastatic Melanoma; Michael B. Atkins, Mark R. Middleton, Paul B. ChapmanSingle-agent chemotherapyDacarbazine and temozolomideNitrosoureasPlatinumsMicrotubule toxinsCombination cytotoxic chemotherapyNitrosourea combinationsTaxane-based combination therapyCisplatin-based combination therapyChemohormonal therapyBiochemotherapyInterferon alpha–based biochemotherapy regimensInterleukin-2–based regimensInterleukin-2 and DTIC/temozolomide combinationsCisplatin and interleukin-2–based biochemotherapy regimensInpatient concurrent biochemotherapy regimensPhase III biochemotherapy trialsOther biochemotherapy investigationsNon–interleukin-2 or interferon-based biochemotherapy combinationsChemotherapy and antiangiogenic or targeted therapyAntiangiogenic agentsAntiapoptosis-inducing agentsSelection of future phase III trialsInterferon Therapy for Melanoma; Ernest C. Borden, Stergios J. Moschos, John M. KirkwoodEndogenous interferons as part of the host response to cancerThe family of interferon proteins and signaling activationMechanisms of antitumor action in melanomaSignaling by interferonsCellular mechanisms of action of interferonsInterferon-alpha-2 in the treatment of melanomaThe future of interferons in melanoma biology and therapyInterleukins and Cellular Therapies for Melanoma; Douglas J. SchwartzentruberPharmacology of interleukin-2Immunologic activity of interleukin-2Systemic effects of interleukin-2Clinical efficacy of high-dose interleukin-2 aloneClinical efficacy of alternate doses, routes, and schedules of interleukin-2 aloneClinical efficacy of interleukin-2 combined with interferon-alphaClinical efficacy of interleukin-2 combined with other cytokines, immune modulators, antibodies, or vaccinesAgents to reduce the toxicity of interleukin-2Predictors of clinical responseOther cytokines for treatment of metastatic melanomaClinical efficacy of interleukin-2 combined with cellular therapyMelanoma Vaccines; Jedd D.Wolchok, Jeffrey S.WeberTumor immunologyAntigen discoveryAdjuvantsVaccine approachesCell vaccinesTransduced cell vaccinesHLA-restricted melanoma-associated antigenic peptidesGanglioside vaccinesAntiidiotypic monoclonal antibodies mimicking ganglioside antigensProtein antigensHeat-shock protein–based vaccinesDNA vaccinationDendritic cell vaccinesRecombinant viral vaccinesCombination strategies and the future of melanoma vaccinesImmune Modulators in the Treatment of Patients with Melanoma; James P. Allison, F. Stephen Hodi, Yvonne M. Saenger, Jedd D. WolchokBiology of CTLA-4–mediated immune inhibitionPreclinical development of anti-CTLA-4 as an anticancer agentAnti-CTLA-4: clinical experience in melanomaEfficacy of CTLA-4 blockade: summary of clinical trials to dateCTLA-4 blockade and immune-related adverse eventsKinetics of responsePatient selection and predictors of toxicity and antitumor responseDose and schedule of anti-CTLA-4 administrationCorrelative immunologic studiesVaccination strategies in combination with CTLA-4 blockadeCombination of CTLA-4 blockade and GM-CSF vaccination in murine modelsClinical investigation of combination CTLA-4 blockade and autologous GM-CSF–secreting tumor vaccinationCTLA-4 blockade with peptide vaccinesOther CTLA-4 antibody and immunotherapy combinationsMelanoma-Specific Targeted Therapies; Paul B. Chapman, David B. Solit, Keith T. FlahertyTargeting cell surface moleculesTargeting receptor tyrosine kinases expressed in melanomaMonoclonal antibodiesTargeting intracellular moleculesThe mitogen-activated protein kinase pathway in melanomaDrugs that inhibit BRAFHsp90 inhibitorsDrugs that inhibit MEKTargeting PI3/AKT pathwayAngiogenesis inhibition in melanomaBiology of MelanomaGenetics and Molecular Pathology of Melanoma; Boris C. Bastian, Daniel Pinkel, Amaya VirosDistinct patterns of epidemiologic, clinical, and histopathologic features in melanomaEmerging melanoma subtypes based on genotypephenotype correlationsMelanomas on sun-exposed sitesMelanomas on relatively or absolutely UV-protected sitesMelanocytic tumors arising without associations to epithelial structuresBiology of Melanocytes and Primary Melanoma; Glenn Merlino, Vincent J. HearingDevelopment of melanoblastsRegulation of specificationRegulation of migrationRegulation of survival and proliferationDifferentiation of melanocytesRegulation of differentiationRegulation of survivalMelanomagenesisFrom melanocyte to melanoma: a multistep processMolecular genetics: early lessons from familial and sporadic melanomaMelanoma: a consequence of homeostatic disruptionMelanoma: cell of originMelanoma and the environmentSun exposure and epidemiologyPhotobiology and melanomaBiology of Melanoma Metastasis; Menashe Bar-Eli, Isaiah J. FidlerThe pathogenesis of melanoma metastasisTranscriptional regulation of melanoma progressionRole of AP-2-α in melanoma progressionRole of CREB/ATF-1 in melanoma progressionInvolvement of ATF-2 in melanoma progressionSNAIL: its regulatory pathway in melanomaMITF: its role in melanoma progressionRegulation of melanoma metastasis by the tumor microenvironmentRole of platelet-activating factor receptorPotential therapeutic approaches to inhibiting melanoma metastasisUsing fully humanized antibodies to MCAM/MUC18 to inhibit tumor growth and metastasis of human melanomaUsing fully humanized neutralizing antibodies to interleukin-8 (ABX-IL-8) to inhibit angiogenesis, tumor growth, and metastasis of human melanomaImmunology of Melanoma; Suzanne L.Topalian, Lieping Chen, Janis M.Taube, Paul F. Robbins, Jedd D.Wolchok, Alan N. HoughtonInnate immunityAdaptive immunityMelanoma antigensGeneral principles for identification of tumor antigens recognized by T cells and antibodiesNonmutated self-antigensMutant melanoma antigens Altered peptide ligands: enhancing the immunogenicity of low-affinity melanoma epitopesExperimental modelsImmune regulation and toleranceCostimulatory/coinhibitory receptorsRegulatory T cellsCytokinesImplications for immunotherapyBiomarkers for Melanoma; Elizabeth A. Grimm, Dave S.B. Hoon, Lyn McDivitt DuncanPotential clinical impact of melanoma biomarkersMelanoma heterogeneityMelanoma biomarker discovery and validation processBiomarkers in early-stage melanomaMolecular markers in primary cutaneous melanomaBiomarkers for later-stage melanomaMolecular markers in sentinel lymph nodesMolecular markers in bloodMolecular markers in metastatic tumorsAdditional CreditsIndex

    1 in stock

    £218.50

  • Immunopatient: The New Frontier of Curing Cancer

    Hatherleigh Press,U.S. Immunopatient: The New Frontier of Curing Cancer

    1 in stock

    Book SynopsisThe inspirational true story of one man's struggle against cancer, as he bravely undergoes an experimental treatment that may offer new hope to cancer patients everywhere.

    1 in stock

    £21.59

  • Tumors of the Pediatric Central Nervous System

    Thieme Medical Publishers Inc Tumors of the Pediatric Central Nervous System

    3 in stock

    Book SynopsisTumors of the Pediatric Central Nervous System, Second Edition, provides readers with both medical management and surgical perspectives on the clinical, pathological, and radiological diagnoses and treatment of pediatric CNS tumors. It includes complete coverage of the latest diagnostic and management techniques, state-of-the-art technologies, and trends in the surgical treatment of pediatric tumors. Highlights of the Second Edition: Contains 19 new chapters on such topics as recent advances in the cytogenetics and molecular biology of pediatric brain tumors, gangliogliomas and miscellaneous spinal cord tumors in children, post-chemotherapy morbidity, and many more Addresses the important issues of long-term chronic treatment of pediatric tumor patients and related outcome measures Includes summary boxes and tables that distill large amounts of information for quick review Written by editors and contributors who are world-renowned experts in the field of pediatric neurosurgery and oncology Neurosurgeons, neurologists, oncologists, radiation oncologists, and pediatricians caring for patients with tumors of the central nervous system will find this book to be an essential resource that they will repeatedly consult as they strive to enhance patient care.

    3 in stock

    £207.10

  • Breast Cancer in the Post-Genomic Era

    Humana Press Inc. Breast Cancer in the Post-Genomic Era

    1 in stock

    Book SynopsisBreast Cancer is the most common tumor in women and the second leading cause of cancer deaths worldwide. Due to breakthroughs in gene profiling, the knowledge of the pathophysiology of the mammary gland had greatly increased over the last decade. In Breast Cancer in the Post Genomic Era, Antonio Giordano, Nicola Normanno, and a panel of international authorities in their field provide a comprehensive approach to the biology, diagnosis, prevention, and treatment of human breast carcinoma. The book provides a comprehensive approach to breast cancer, describing the use of gene profiling techniques to distinguish specific features of individual carcinomas, as well as emerging novel therapeutic approaches to treatment. Additional chapters cover the use of transgenic mice to model human breast cancer and the role of the EGF-CFC family in mammary gland development and neoplasia. Breast Cancer in the Post Genomic-Era succeeds in looking at breast cancer pathogenesis, diagnosis, and treatment under a more comprehensive light, and is a valuable resource for any Radiation or Surgical Oncologist, Cancer Biologist or Pathologist.Table of ContentsPotential Contributors and Temptative Titles Section I: The biology of the mammary gland: Jose Russo, Breast Cancer Research Laboratory, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA Title: Mammary gland development Gilbert H. Smith Mammary Biology and Tumorigenesis Laboratory, Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Bethesda, 20892, Maryland Title: Mammary gland, stem cells and breast cancer Section II: The genetic background of breast cancer Barbara L. Weber, Abramson Family Cancer Research Institute, University of Pennsylvania Cancer Center, 514 BRB II/III, 421 Curie Blvd, Philadelphia, PA 19104, USA Title: The genetic of breast cancer: application in clinical practice Ashok R. Venkitaraman, University of Cambridge, CR UK Department of Oncology and The Medical Research Council Cancer Cell Unit, Hutchison/MRC Research Centre, Hills Road, Cambridge, CB2 2XZ, U.K Title: Cancerogenesis associated with mutations in BRCA genes Section III: Epigenetic and molecular alterations in breast cancer Nancy E. Davidson, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Room 409, Baltimore, MD 21231 Title: DNA methylation in breast cancer Antonio Giordano, Sbarro Institute for Cancer Research and Molecular Medicine, College of Science and Technology, Temple University, 1900 North 12th Street, Philadelphia, PA 19122, USA Title: Alterations of cell cycle regulatory genes in breast cancer David S. Salomon, Tumor Growth Factor Section, Mammary Biology & Tumorigenesis Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bldg 10, Rm. 5B39, Bethesda, Maryland 20892 Title: Role of the cripto (EGF-CFC) family in mammary gland development and neoplasia William J Gullick, Department of Biosciences, University of Kent at Canterbury, Canterbury, Kent CT2 7NJ Title: Type I growth factor receptors and their ligands in breast cancer: clinical significance and future prospects for treatment William J. Muller, Institute for Molecular Biology and Biotechnology, Department of Biology, McMaster University, Hamilton, Ontario, Canada L8S 4K1 Title: Transgenic mouse models of breast cancer as model to study oncogene mediated signal transduction Section IV: New tools for diagnosis and prognostic assessment in breast cancer Eric S. Lander, Whitehead Institute/MIT Center for Genome Research, One Kendall Square, Building 300, Cambridge, Massachusetts 02139, USA Title: Gene expression profiling in breast cancer: clinical applications Emanuel F. Petricoin III, Center for Applied Proteomics and Molecular Medicine, George Mason University, 10900 University Boulevard, MS 4E3, Manassas, VA 20110 Title: Proteomics in breast cancer Section V: Novel therapeutic approaches Erik P. Winer, Dana-Farber Cancer Institute, 44 Binney St, D1210, Boston, MA 02115, USA. Title: The endocrine therapy of breast cancer in the era of the aromatase inhibitors Nicola Normanno, Cell Biology and Preclinical Models Unit, INT-Fondazione Pascale, Naples, Italy Title: Signal transduction inhibitors for treatment and prevention of breast cancer Jose Baselga, Vall d'Hebron, University Hospital, Department of Medical Oncology, Pg Vall d'Hebron, 119-129, E-08035 Barcelona, Spain. Title: Monoclonal antibodies in breast cancer therapy: current status and future development Carlos L. Arteaga, Department of Cancer Biology, Vanderbilt University Medical Center, 2220 Pierce Avenue, 777 PRB, Nashville, TN 37232 USA Title: TGFbeta antagonists: a novel approach fro treatment of breast cancer? Francesco Perrone, Clinical Trials Unit, INT-Fondazione Pascale, Naples, Italy Integration of target based agents in current protocols of breast cancer therapy

    1 in stock

    £84.07

  • Amazon Digital Services LLC - Kdp Life Reconstructed

    15 in stock

    Book Synopsis

    15 in stock

    £12.93

  • Manual of Interventional Oncology

    Thieme Medical Publishers Inc Manual of Interventional Oncology

    Out of stock

    Book SynopsisThis Manual of Interventional Oncology by Douglas Coldwell is the culmination of more than 30 years of training, hands-on practice, and skills learned from oncology colleagues. The successful practice of interventional oncology (IO) requires familiarity with all cancer interventions, and the ability to recognize each of their strengths and weaknesses. Acquiring basic knowledge of all facets of the vast, ever-evolving cancer treatment paradigm enables greater understanding of how IO fits into the broad cancer management continuum. The first five chapters lay a solid foundation, detailing essentials of medical and surgical oncology and radiation, followed by interventional radiology cancer treatments and agents used in cancer chemotherapy. Twelve cancer-specific chapters cover tumor management and discussion of minimally invasive, image-guided tumor ablation techniques for each type of cancer, as well as IO for pain management and palliative care. Key Highlights IO interventions for prevalent cancers such as colorectal, pancreatic, prostate, liver, bladder, breast, lung, and gynecologic - and less common pathologies including neuroendocrine tumors of the gastrointestinal tract and cholangiocarcinoma More than 125 illustrations accompany succinct discussions of pathology, epidemiology, genetics, staging, treatment, outcomes, and IO options for each type of tumor An overview of clinical trials provides a glimpse of future IO innovations A road map to a successful IO career includes pearls gleaned from years of managing a thriving practice This definitive guide is a must-have for clinicians working in the field of vascular and interventional radiology. It provides interventional radiologists with the necessary building blocks, information, and techniques to thrive in this rapidly evolving specialty.Table of Contents1 Essentials of Medical Oncology 2 Essentials of Surgical Oncology 3 Essentials of Radiation Oncology 4 Interventional Radiology in the Treatment of the Cancer Patient 5 Chemotherapeutic Agents 6 Colorectal Cancer 7 Cancer of the Pancreas 8 Carcinoid Tumor (Neuroendocrine Tumors of the Gastrointestinal Tract) 9 Hepatocellular Carcinoma 10 Cholangiocarcinoma 11 Lung Cancer (Non-Small Cell) 12 Head and Neck Cancer 13 Renal Cell Carcinoma 14 Urothelial Cancer and Transitional Cell Cancer 15 Prostate Cancer 16 Breast Cancer 17 Gynecologic Tumors 18 Clinical Trials and Interventional Oncology 19 Building an Interventional Oncology Practice

    Out of stock

    £999.99

  • A Mother's Choice

    Allen & Unwin A Mother's Choice

    Book SynopsisOn May 1st 2016 Elle Halliwell, an Australian fashion editor, was diagnosed with leukaemia. Two weeks later just as she was telling friends and family about the grim diagnosis she found out she was 4 weeks pregnant with her first child. She was faced with an impossible choice: either terminate her unborn baby and begin the treatment that gave her the best chance of survival, or continue with the pregnancy and delay effective intervention for her cancer, a course that could lead to her death.Elle chose her baby over herself, a mother's choice. Her memoir details her illness, her pregnancy, and against all the odds, the ultimate triumph of giving birth to her son in December 2016. Almost a year later she is still on the road to recovery but has discovered a new passion for nutrition and healthy living. Her journey remains hard but the trials of the last year and a half have made her more determined than ever to live well and regain her health for the sake of her family and her son. A Mother's Choice is compelling, moving and inspiring.

    £18.32

  • Rediscovering Cancer: From Mechanism to Therapy

    Apple Academic Press Inc. Rediscovering Cancer: From Mechanism to Therapy

    5 in stock

    Book SynopsisThis volume presents a snapshot of some of the most important ongoing research in cancer. With cancer as the second leading cause of death worldwide, extensive research is going on globally to decipher the molecular mechanism underlying cancer that will help in finding better targets for drug therapy. The book brings together new research on molecular mechanism and cancer therapeutics in one place. With chapters from experts in their respective fields, chapters cover molecular mechanisms, etiology, prognosis, detection, and treatment of cancer. Emphasis has been given to the intricate mechanism behind the deregulation of cell division, disruption of cell cycle check points, mutation in oncogenes and tumor suppressor genes, apoptosis, and erratic cell signaling. The book discusses in detail topics such as angiogenesis and tumor microenvironment, which are increasingly receiving attention, especially in the field of neoplastic vascularization and metastasis. The book also includes chapters detailing the current understanding and the future perspective of cancer stem cells. Trade Review“One of the few books that sheds light on the causes and mechanisms of the disease itself as well as the possible therapeutic aspects. The book contains intricately woven chapters on cell cycle checkpoints on cancer, oncogenes, tumor suppressor genes, apoptosis, cell signaling, angiogenesis and metastasis. The modern approaches toward cancer diagnosis and therapy, like cancer stem cell, immunotherapy, chemotherapy, and nanoparticle-based therapy, have also been thoroughly covered. The contributors of each and every chapter are experts in their respective field and have summarized their research findings in a very concise manner. The best part of the book is that the chapters have been grouped into major divisions to have continuity and synchronization among them. The volume can be used by students and researchers who are working in the field of cancer. It covers new approaches toward cancer treatment and therefore may be useful handbook for clinicians. Overall, this informative volume covers the present knowledge and future direction on the field of cancer research.”— Dr. Naibedya Chattopadhyay, Scientist G, CSIR-Central Drug Research Institute, Lucknow, IndiaTable of ContentsGenetic Instability in Cancer. Oncogenesis and Telomerase Activity in Cancer. Cell Cycle Checkpoints in Cancer. Angiogenesis, Its Importance and Implication in Tumor Growth and Progression and in Anticancer Therapy: An Update. The Tumor Microenvironment and Metastasis. Apoptosis: A Regulatory Mechanism in Cancer. Cytoplasmic Signaling Circuitry: An Important Trait of Cancer. Cancer: An Overview of Risk Factors. Single Nucleotide Polymorphisms as Susceptibility Markers for Cancer. Dietary Phytochemicals in the Prevention and Therapy of Cancer: Modulation of Molecular Targets. Health Benefits and Preventive Effects of Common Beverages in Cancer. Cancer Chemotherapy. Non-Coding RNAs: The New Reins in Malignancies. Epigenetics in Cancer Prevention and Therapy: Role of Phytochemicals. Cancer Stem Cell: Current Understanding and Future Perspectives. Tumor Microenvironment and Cancer Stem Cells: Therapeutic Potential of Epigenetic Inhibitors to Target CSCs. Nanoparticles in Cancer Therapy. Cancer Immunotherapy: Extending New Horizons in Cancer Treatment.

    5 in stock

    £146.30

  • James Ellesmere Keto Or Atkins?

    Out of stock

    Book Synopsis

    Out of stock

    £32.29

  • Rowanvale Books Ltd Staying Alive

    15 in stock

    Book Synopsis

    15 in stock

    £19.12

  • Eyelid Tumors

    Manson Publishing Ltd Eyelid Tumors

    1 in stock

    Book SynopsisThis book provides a practical, superbly illustrated guide to the clinical diagnosis of eyelid tumors and the surgical procedures used for tumor excision and eyelid reconstruction. In this completely revised and updated Second Edition, there are new chapters on pathology and radiosurgery, procedures have been amended to reflect current practice, all the surgical illustrations have been redrawn in full color, and selected clinical photographs have been added or replaced.The first section of the book covers differential diagnosis and features over 100 full color photographs of benign and malignant eyelid tumors and inflammatory conditions, accompanied by concise descriptions of the clinical presentation and the course of these lesions. This section is designed to enable the clinician to distinguish accurately lesions requiring biopsy and/or surgical removal from those that should be treated medically or observed for changes.In the second section, the author describes the surgical anatomy of the eyelids and surrounding structures, and provides currently accepted procedures for eyelid tumor biopsies, the most effective techniques for tumor removal, and upper and lower lid reconstruction. Key steps are illustrated by over 200 full color drawings and photographs.With its emphasis on the more common conditions, and its clear, user-friendly and practical approach, Eyelid Tumors is a valuable source of reference for ophthalmic clinicians and surgeons, plastic and reconstructive surgeons, dermatologists and pathologists.Trade ReviewWell written, practical and concise. Excellent colour illustrations and photographs fill this book and complement its easily readable text...an exceptional resource in managing patients with eyelid tumors.—Journal of Cosmetic and Laser SurgeryTable of ContentsDiagnosis and Management: Differential Diagnosis of Eyelid Tumours. Malignant Tumours. Benign Tumours and Related Conditions. Treatment of Eyelid Tumors. Reconstruction of the Eyelids: Surgical Anatomy. General Principles of Eyelid Reconstruction and Radiosurgery. Lower Eyelid Reconstruction. Upper Eyelid Reconstruction. Repair of Defects that do not involve Eyelid Margins. Reconstruction of the Medial and Lateral Canthi.

    1 in stock

    £170.00

  • From Oncology Nursing to Coping with Breast

    Taylor & Francis Ltd From Oncology Nursing to Coping with Breast

    Out of stock

    Book SynopsisMany healthcare professionals that I've encountered refer to a patient's cancer journey; indeed I had an article published describing a patient's journey through biological therapy. This particular case history described my involvement with a medical doctor's experience of renal cell carcinoma and self-administration of immunotherapy. He was very keen to share his experience to educate and inform other health professionals and I now find myself in a similar situation.'I have 'journeyed' from nurse to patient when diagnosed with grade 3-breast cancer. Of course, I've experienced various health problems before this time, but I never spent a night in hospital, unlike members of my family who have experienced serious illness and hospitalisation on several occasions. Consequently I've always regarded myself in the caring role amongst family members and over the years I've used my nursing knowledge and skills to help them deal with both the physical and psychological issues of their various disease processes. However, being diagnosed with breast cancer has now changed me from nurse and carer into a vulnerable ill person with doubts and fears for my future. To restore some sense of purpose while on sick leave and help me to get through each treatment stage, I decided to keep a daily journal of my experience.Trade Review'This book adds to the canon of literature that is the patient perspective of their illness by, unusually, documenting the experience of a nurse-cum-patient. Any text that allows us to explore the lived experience and therefore, we hope, learn something about our patients, our care and ourselves is a boon to the library.' CANCER CARE NEWS 'A good book for a nurse who is newer to the field or even a patient undergoing breast cancer treatment.' DOODY'S REVIEW SERVICETable of ContentsKate’s story

    Out of stock

    £20.89

  • Colorectal Cancer

    John Wiley & Sons Inc Colorectal Cancer

    Out of stock

    Book SynopsisNurses should have the most up-to-date knowledge to provide accurate information and competent nursing care to patients with colorectal cancer. Swan addresses those issues in a very thorough and comprehensive manner. Chapters on the role of the colorectal nurse specialist, epidemiology and genetics, diagnosis, investigations and different treatments make this book essential reading for any colorectal nurse specialist. Colorectal cancer is the third most common cancer in men, and the second most common cancer in women in the UK. Colorectal Cancer is a very important book in this field. As mortality statistics continue to rise, this book addresses the issues surrounding colorectal cancer. It is vital to care for and attend to the needs of these patients.Table of ContentsContributors. Preface. Acknowledgements. Chapter 1: The role of the colorectal nurse specialist (Elaine Swan). Chapter 2: Aetiology of colon and rectal cancer (Jonathan Stewart). Chapter 3: Epidemiology and genetics (Lucy Burgess). Chapter 4: Diagnosis and investigations (Yvette Perston). Chapter 5: Treatments (Shelley Biddles). Chapter 6: Consequences of rectal surgery (Jane Winney). Chapter 7: Further treatment: chemotherapy and radiotherapy (Helen Ferns). Chapter 8: Palliative nursing care (Claire Taylor). Index.

    Out of stock

    £999.99

  • But I Still Have My Fingerprints

    CavanKerry Press But I Still Have My Fingerprints

    15 in stock

    Book SynopsisPoems centered on survival and perseverance in the face of long-term illness. Delivered a diagnosis of acute myeloid leukemia with a ten percent prognosis for survival, Dr. Dianne Silvestri surrenders her white coat for a hospital gown. Aided by her attentive medical team, family, and friends, she navigates the surreal world of chemotherapy, stem cell transplantation, and subsequent threats from graft-versus-host disease and serious infections of her compromised immune system.But I Still Have My Fingerprints speaks to the difficulties of “surviving survival.” With a clear eye for irony and analogy and a commitment to curiosity and truth, Silvestri writes through her struggles and victories. She gives us poems with unique perspectives, fresh images, and unquenchable optimism, in her perseverance to redefine life beyond what was lost.Trade Review“Silvestri’s fine lyric poems are written with the clear vision of the physician who herself becomes the patient with a serious illness (‘beached / my white coat surrendered’). She travels with honesty and courage her ‘long essential / diversion’ from the everyday of her life. There is the night phone call with bad news (‘I endure for the verdict at dawn’), followed by the complicated journey through pain, treatments, fears, losses, consolations, leading to a ‘first-ditch list’ of hopes. An inspiring, merciful, beautifully-written collection.” * Ann Taylor, author of 'Sortings' *"Dianne Silvestri, MD, a poet as well as a retired dermatologist, has provided readers with the emotionally moving and artistically creative story of her cancer diagnosis, treatment, and survivorship... Silvestri has accomplished a medical humanities miracle in integrating personal candor, vivid exposition of medical procedures, and distinctive poetic techniques." * Journal of Poetry Therapy *Table of ContentsDear DoctorEmergency Phone Call from My Doctor, 11pmCosmic QuestionsDaunorubicinChemotherapyThe Night PhlebotomistDoctor as PatientFor the Patients with Hair LossSkullcapPoem for GeorgeA Bag of BloodThe Hospital MailHospital HousekeepingAubadeConversation with My GrandsonSeated on My Hospital BedBone Marrow BiopsyOff ScriptDonor SearchDear Healthy 28-Year-Old ManIsolation Room, Leukemia FloorCountdown to a New BirthdayAwaiting ReconstitutionSwallow ThisChimeraDrug-Induced Tendon TearDemolitionAdvance DirectivesTime OutAfter a Month AwayIt Would Be So Nice To HaveBack Home, Day 459Lying on the Patient History FormSummer’s ReprieveCitrus aurantiumGraft vs. HostThe Nurses ThereChoosing the Right Pumpkin, Farm Stand, Natick, MAAppointment at the Oncology ClinicMRIFeature Film: Drug Study KEP DR78PTSDDarkroom in the Converted Laundry RoomReadmitted: This Time to the Overflow WardYou May Resume Your Normal ActivitiesPlease Define LongerA Club for Those of Us Who Almost DiedRunoffWith FeathersWanted: LustFlashback on a Sunny DayRose Quartz Geode I Found in the WoodsMaintenance FatigueWaiting Room WaitingRetail TherapyVictory GardenAn End to the EndsNew LifeGlossaryAcknowledgments

    15 in stock

    £15.00

  • Gay and Bisexual Men Living with Prostate Cancer

    Harrington Park Press Inc Gay and Bisexual Men Living with Prostate Cancer

    1 in stock

    Book SynopsisThis book provides an overview of research and practice dealing with the specific needs of gay and bisexual men living with prostate cancer, as well as the special psychosocial needs of their partners. The intention is twofold: to provide insight into the unique experiences and concerns of gay or bisexual men living with prostate cancer in order to inform and assist future research, clinical practice and supportive care, and policy; and to ensure that the needs of gay and bisexual men are recognized and advanced on the mainstream prostate cancer agenda. Featuring both cutting-edge research and powerful portraits of gay and bisexual men living with prostate cancer, this book will be indispensable for health care, oncology, and mental health practitioners who seek to address their specific experiences and challenges.Trade ReviewThe challenges for gay and bisexual men with prostate cancer have remained poorly described for years – until this book. Covering multiple aspects of the diagnostic, treatment, and recovery periods, the studies presented illuminate the unique challenges for this population. The stories of individual gay men in the final chapters are especially poignant and highlight where the traditional medical establishment can improve services to these men. -- Anne Katz, editor of Oncology Nursing ForumThis is the definitive book covering the pioneering research that has helped make visible the specific needs and experiences of gay and bisexual men with prostate cancer. It is essential reading from the leaders in the field. -- Anthony Lowe, chief executive officer, Prostate Cancer Foundation of AustraliaRequired reading for urologists and oncologists who treat gay and bisexual men as well as for mental health practitioners. I would also recommend it to gay men contemplating treatment for prostate cancer and to their husbands and/or sexual partners as well. -- Jack Drescher, Clinical Professor of Psychiatry, Columbia University College of Physicians and SurgeonsTable of ContentsForeword, by Jonathan Bergman and Mark S. LitwinIntroduction, by Jane M. Ussher, Janette Perz, and B. R. Simon RosserSection 1: Gay and Bisexual Men’s Experiences of Prostate Cancer: What Does Research Tell Us?1. Understanding Prostate Cancer in Gay, Bisexual, and Other Men Who Have Sex with Men and Transgender Women: A Review of the Literature, by B. R. Simon Rosser, Shanda L. Hunt, Benjamin D. Capistrant, Nidhi Kohli, Badrinath R. Konety, Darryl Mitteldorf, Michael W. Ross, Kristine M. Talley, and William West2. Threat to Gay Identity and Sexual Relationships: The Consequences of Prostate Cancer Treatment for Gay and Bisexual Men, by Jane M. Ussher, Janette Perz, Duncan Rose, Gary W. Dowsett, and David M. Latini3. Integrating Post-Prostatectomy Sexuality: The Couple’s Journey, by Daniela Wittmann4. “My partner is my family”: An Interdependence and Communal Coping Approach to Understanding Prostate Cancer in Same-Sex Male Couples, by Charles Kamen and Lynae Darbes5. Psychological Adjustment in Gay and Bisexual Men after Prostate Cancer, by Michael A. Hoyt and Brett M. Millar6. The Social Dimensions of Prostate Cancer in Gay Men’s Sexuality, by Gary W. Dowsett, Duane Duncan, Andrea Waling, Daniel R. du Plooy, and Garrett P. Prestage7. Gay Men and Prostate Cancer: Learning from the Voices of a Hidden Population, by Murray Drummond, James Smith, and Shaun FiliaultSection 2: Cancer Care and Support for Gay and Bisexual Men with Prostate Cancer8. Lack of Information and Unmet Needs: Gay and Bisexual Men’s Sexual Communication with Healthcare Professionals about Sex after Prostate Cancer, by Duncan Rose, Jane M. Ussher, and Janette Perz9. Prostate Cancer Treatment Decision-Making and Survivorship Considerations among Gay and Bisexual Men: Implications for Sexual Roles and Functioning, by Gwendolyn P. Quinn, Matthew B. Schabath, and Clement K. Gwede10. Sexual Aids for Gay and Bisexual Men and Transgender Women after Prostate Cancer Treatments, by Erik Wibowo and Richard Wassersug11. Experiences of Sexual Rehabilitation after Prostate Cancer: A Comparison of Gay and Bisexual Men with Heterosexual Men, by Jane M. Ussher, Duncan Rose, Janette Perz, Gary W. Dowsett, andAndrew Kellett12. Illness Intrusiveness and Social Support in Gay and Bisexual Men with Prostate Cancer, by Tae L. Hart, Crystal Hare, and David M. Latini13. The Effects of Radiation Therapy for Prostate Cancer on Gay and Bisexual Men’s Experiences of Mental Health, Sexual Functioning and Behavior, Sexual Identity, and Relationships, by William West, B. R. Simon Rosser, Benjamin D. Capistrant, Beatriz Torres, Badrinath R. Konety, Darryl Mitteldorf, Michael W. Ross, and Kristine M. Talley14. Toward a More Comprehensive Model of Prostate Cancer Care Inclusive of Gay and Bisexual Men and Transgender Women, by Donald Allensworth-Davies, Thomas O. Blank, Brian de Vries, and Emilia Lombardi15. Malecare: Twenty Years of Innovation and Service to Gay and Bisexual Men and Transgender Women with Prostate Cancer, by Darryl MitteldorfSection 3: Personal Experiences16. “Losing My Chestnut”: One Gay Man’s Wrangle with Prostate Cancer—Ten Years On, by Gary W. Dowsett17. What about Me?, by Ross Henderson18. An Invader in the Pleasure Dome, by Perry Brass19. Looking Back: Engaging Prostate Cancer as a Gay Man at the Turn of the Twenty-first Century, by Gerald Perlman20. A Shared Decision-Making Approach to Assessing Prostate Cancer Risk: A Gay Diary Case Study, by B. R. Simon Rosser, William West, and Badrinath R. KonetyGlossary About the Editors and Contributors Index

    1 in stock

    £64.00

  • Gay and Bisexual Men Living with Prostate Cancer

    Harrington Park Press Inc Gay and Bisexual Men Living with Prostate Cancer

    1 in stock

    Book SynopsisThis book provides an overview of research and practice dealing with the specific needs of gay and bisexual men living with prostate cancer, as well as the special psychosocial needs of their partners. The intention is twofold: to provide insight into the unique experiences and concerns of gay or bisexual men living with prostate cancer in order to inform and assist future research, clinical practice and supportive care, and policy; and to ensure that the needs of gay and bisexual men are recognized and advanced on the mainstream prostate cancer agenda. Featuring both cutting-edge research and powerful portraits of gay and bisexual men living with prostate cancer, this book will be indispensable for health care, oncology, and mental health practitioners who seek to address their specific experiences and challenges.Trade ReviewThe challenges for gay and bisexual men with prostate cancer have remained poorly described for years – until this book. Covering multiple aspects of the diagnostic, treatment, and recovery periods, the studies presented illuminate the unique challenges for this population. The stories of individual gay men in the final chapters are especially poignant and highlight where the traditional medical establishment can improve services to these men. -- Anne Katz, editor of Oncology Nursing ForumThis is the definitive book covering the pioneering research that has helped make visible the specific needs and experiences of gay and bisexual men with prostate cancer. It is essential reading from the leaders in the field. -- Anthony Lowe, chief executive officer, Prostate Cancer Foundation of AustraliaRequired reading for urologists and oncologists who treat gay and bisexual men as well as for mental health practitioners. I would also recommend it to gay men contemplating treatment for prostate cancer and to their husbands and/or sexual partners as well. -- Jack Drescher, Clinical Professor of Psychiatry, Columbia University College of Physicians and SurgeonsTable of ContentsForeword, by Jonathan Bergman and Mark S. LitwinIntroduction, by Jane M. Ussher, Janette Perz, and B. R. Simon RosserSection 1: Gay and Bisexual Men’s Experiences of Prostate Cancer: What Does Research Tell Us?1. Understanding Prostate Cancer in Gay, Bisexual, and Other Men Who Have Sex with Men and Transgender Women: A Review of the Literature, by B. R. Simon Rosser, Shanda L. Hunt, Benjamin D. Capistrant, Nidhi Kohli, Badrinath R. Konety, Darryl Mitteldorf, Michael W. Ross, Kristine M. Talley, and William West2. Threat to Gay Identity and Sexual Relationships: The Consequences of Prostate Cancer Treatment for Gay and Bisexual Men, by Jane M. Ussher, Janette Perz, Duncan Rose, Gary W. Dowsett, and David M. Latini3. Integrating Post-Prostatectomy Sexuality: The Couple’s Journey, by Daniela Wittmann4. “My partner is my family”: An Interdependence and Communal Coping Approach to Understanding Prostate Cancer in Same-Sex Male Couples, by Charles Kamen and Lynae Darbes5. Psychological Adjustment in Gay and Bisexual Men after Prostate Cancer, by Michael A. Hoyt and Brett M. Millar6. The Social Dimensions of Prostate Cancer in Gay Men’s Sexuality, by Gary W. Dowsett, Duane Duncan, Andrea Waling, Daniel R. du Plooy, and Garrett P. Prestage7. Gay Men and Prostate Cancer: Learning from the Voices of a Hidden Population, by Murray Drummond, James Smith, and Shaun FiliaultSection 2: Cancer Care and Support for Gay and Bisexual Men with Prostate Cancer8. Lack of Information and Unmet Needs: Gay and Bisexual Men’s Sexual Communication with Healthcare Professionals about Sex after Prostate Cancer, by Duncan Rose, Jane M. Ussher, and Janette Perz9. Prostate Cancer Treatment Decision-Making and Survivorship Considerations among Gay and Bisexual Men: Implications for Sexual Roles and Functioning, by Gwendolyn P. Quinn, Matthew B. Schabath, and Clement K. Gwede10. Sexual Aids for Gay and Bisexual Men and Transgender Women after Prostate Cancer Treatments, by Erik Wibowo and Richard Wassersug11. Experiences of Sexual Rehabilitation after Prostate Cancer: A Comparison of Gay and Bisexual Men with Heterosexual Men, by Jane M. Ussher, Duncan Rose, Janette Perz, Gary W. Dowsett, andAndrew Kellett12. Illness Intrusiveness and Social Support in Gay and Bisexual Men with Prostate Cancer, by Tae L. Hart, Crystal Hare, and David M. Latini13. The Effects of Radiation Therapy for Prostate Cancer on Gay and Bisexual Men’s Experiences of Mental Health, Sexual Functioning and Behavior, Sexual Identity, and Relationships, by William West, B. R. Simon Rosser, Benjamin D. Capistrant, Beatriz Torres, Badrinath R. Konety, Darryl Mitteldorf, Michael W. Ross, and Kristine M. Talley14. Toward a More Comprehensive Model of Prostate Cancer Care Inclusive of Gay and Bisexual Men and Transgender Women, by Donald Allensworth-Davies, Thomas O. Blank, Brian de Vries, and Emilia Lombardi15. Malecare: Twenty Years of Innovation and Service to Gay and Bisexual Men and Transgender Women with Prostate Cancer, by Darryl MitteldorfSection 3: Personal Experiences16. “Losing My Chestnut”: One Gay Man’s Wrangle with Prostate Cancer—Ten Years On, by Gary W. Dowsett17. What about Me?, by Ross Henderson18. An Invader in the Pleasure Dome, by Perry Brass19. Looking Back: Engaging Prostate Cancer as a Gay Man at the Turn of the Twenty-first Century, by Gerald Perlman20. A Shared Decision-Making Approach to Assessing Prostate Cancer Risk: A Gay Diary Case Study, by B. R. Simon Rosser, William West, and Badrinath R. KonetyGlossary About the Editors and Contributors Index

    1 in stock

    £32.30

  • The Washington Manual of Cardio-Oncology: A

    Wolters Kluwer Health The Washington Manual of Cardio-Oncology: A

    15 in stock

    Book SynopsisWritten by experts in cardiovascular disease, hematology, and oncology, The Washington Manual® of Cardio-Oncology: A Practical Guide for Improved Cancer Survivorship is a clinically relevant, easy-to-use primer on the detection, management, and improved cardiovascular-based patient outcomes in adults undergoing treatment for cancer or who have previously survived cancer therapy. Edited by Drs. Daniel J. Lenihan, Joshua D. Mitchell, and Kathleen W. Zhang, this concise yet comprehensive manual provides high-yield information that reflects today’s advances in risk stratification, early diagnosis, and treatment of cardiovascular disease—all in an easy-access, concisely bulleted format for on-the-go reference. Discusses the multitude of complex adverse effects of chemotherapy, targeted therapy, immunotherapy, and radiation therapy to help optimize quality of life and prolong survival in this vulnerable patient population. Includes chapters on how cancer therapy affects the myocardium, valves, pericardium and cardiac electrical system including handy reference tables on typical side effects of commonly used cancer therapies. Provides practical guidance in an easy-to-follow format that covers definition, associated drugs/therapies, epidemiology, diagnosis (history, physical exam, and diagnostic testing), treatment, and outcome/prognosis. Covers the role of non-invasive imaging modalities in the diagnosis and screening for cardiovascular disease including echocardiography, MRI, and nuclear imaging. Addresses frequently encountered clinical scenarios such as preoperative or pre-high-risk treatment evaluation with up-to-date expert consensus recommendations. Details emerging treatments and optimal use of non-invasive imaging in cardiac amyloidosis. Features easy-to-use flow-charts and tables that aid in the differentiation of cardiac masses. The Washington Manual® is a registered mark belonging to Washington University in St. Louis to which international legal protection applies. The mark is used in this publication by Wolters Kluwer Health under license from Washington University. Enrich Your eBook Reading Experience Read directly on your preferred device(s),such as computer, tablet, or smartphone. Easily convert to audiobook,powering your content with natural language text-to-speech.

    15 in stock

    £70.30

  • Springer Nature Switzerland AG Atlas of Early Neoplasias of the Gastrointestinal

    Out of stock

    Book SynopsisThe latest edition of this text provides a comprehensive update on the current standards and newest skills in diagnostic endoscopy for pre/neoplastic lesions of the upper and lower gastrointestinal tract. The atlas outlines procedural requirements and strategies for detection and endoscopic staging (prediction of pT category) of small and minute early cancers, and presents endoscopic and high-resolution endosonographic criteria for submucosal invasiveness. The three major resection techniques, including risk profiles, and differential indications and contraindications for each technique are also outlined. In addition to thoroughly revised chapters from the previous edition, the atlas features new content on submuscosal neoplasias in the GI tract, new magnifying images of early gastric neoplasias, and new endoscopic images of adenoma, dyplasia, inflammatory bowel disease, and early cancer in the duodenum and small bowel.Written by experts in the field, Atlas of Early Neoplasias of the Gastrointestinal Tract: Endoscopic Diagnosis and Therapeutic Decisions, Second Edition is a valuable resource that will improve the diagnostic skills of endoscopists.Trade Review“The audience is Western gastroenterologists seeking to improve their detection of early gastrointestinal neoplasms. It is a not a book that teaches advanced therapeutic technique, rather it is a book that develops the skill to first identify and describe early neoplasia. … This book does an excellent job of covering the macroscopic and histological identification of early gastrointestinal neoplasias. … This book stands alone in terms of its quality and content.” (Peter Nau, Doody's Book Reviews, July 19, 2019)Table of ContentsA. General Principles of Endoscopy for Early Gastrointestinal Neoplasias 1. Endoscopic Detection and Analysis of Mucosal Neoplastic Lesions: Enhanced Imaging and Tumor Morphology Frieder Berr, Thierry Ponchon, Toshio Uraoka 2. Histopathology of Early Mucosal Neoplasias: Morphologic Carcinogenesis in the GI TractDaniel Neureiter, Tobias Kiesslich 3. Principles of Endoscopic Resection: Diagnostic and Curative Resection of Mucosal NeoplasiasTsuneo Oyama, Naohisa Yahagi 4. Subepithlial Gastrointestinal Tumors: Diagnosis and Indications for Resection Frieder Berr, Juergen Hochberger, Tsuneo Oyama5. High-resolution Endoscopic Ultrasound: Clinical T-Staging of Superficial and Subepithelial Gastrointestinal NeoplasiasHans Seifert, Daisuke Kikuchi, Naohisa Yahagi 6. Endoscopic Screening and Surveillance: Indications and Standards Thierry Ponchon, Frieder Berr, Tsuneo OyamaB. Organ-specific Endoscopic Analysis of Early Neoplasias 7. Squamous Cell-lined Esophagus and Hypopharynx: Mucosal NeoplasiasTsuneo Oyama 8. Columnar Epithelium-lined (Barrett´s) Esophagus: Mucosal NeoplasiasPierre Deprez, Takashi Toyonaga 9. Stomach: Mucosal NeoplasiasTsuneo Oyama 10. Duodenum and Small Bowel: Mucosal NeoplasiasMotohiko Kato, Naohisa Yahagi, Thierry Ponchon 11. Colorectum: Mucosal NeoplasiasAndrej Wagner, Tadateru Maehata, Frieder Berr, Naohisa Yahagi12. Chronic Inflammatory Bowel Disease in Remission: Mucosal NeoplasiasNaohisa Yahagi, Tadateru Maehata, Atsushi Nakayama 13. Appendix: Standard Terminology

    Out of stock

    £98.99

  • Springer Nature Switzerland AG Liver Transplantation and Hepatobiliary Surgery:

    1 in stock

    Book SynopsisIn the past, liver resections and liver transplantations were performed by different surgical teams, with very little interplay between the two. However, the evolution toward more complex operations called for an increasingly intense interaction between these surgical techniques: split liver and living donor liver transplantation have become popular in the transplant community, utilizing the Coinaud segmental anatomy in a very sophisticated way, while portal and arterial resection and reconstruction have become indispensable methods for treating Klatskin tumors infiltrating the hepatic hilum. This book offers a complete overview of the connections between liver transplantation and hepatobiliary surgery. It focuses on ex situ techniques for resection of tumors at the suprahepatic confluence, with or without venous reconstruction, and on total vascular exclusion of the liver with the aid of a venovenous bypass that should be a surgical option for referral centers in hepatopancreatobiliary surgery. By taking into consideration the development of minimally invasive liver surgery, it will introduce readers to a variety of new perspectives such as: vascular exclusion techniques with or without extracorporeal circulation, hemodynamic implications and lessons learned from liver transplant surgery, and technical details on pediatric transplantation and its informative role in modern biliary tract surgery. Trade Review Table of Contents

    1 in stock

    £66.49

  • The Thorax

    Springer Nature Switzerland AG The Thorax

    Out of stock

    Book SynopsisThis book highlights the differences, in terms of neoplastic dissemination pathways, between various types of thoracic cancers. It presents and discusses a comprehensive schematic overview of tumors of the lung parenchyma, of the mediastinum, of the pleura, and of the chest wall. For each tumor, it details the local spread and the lymphatic and vascular dissemination, and it describes the challenging staging of lung tumors with mutations. Illustrations and artwork enrich the content and help readers to understand and visualize tumor spread. The book is of great interest to professionals involved in the study, diagnosis and treatment of thoracic pathologies, as well as to residents in radiology, oncology and pulmonology.Table of ContentsChapter 1: Mechanisms of tumour dissemination in thoracic neoplasms.- Chapter 2: Radiological Signs of Tumour Dissemination.- Chapter 3: NSCLC: common types.- Chapter 4: NSCLC: rare types.- Chapter 5: Pulmonary neuroendocrine tumours.- Chapter 6: Tumours of the thymus.- Chapter 7: Other Mediastinal tumours.- Chapter 8: Tumours od the Pleura.- Chapter 9: Tumours of the chest wall.

    Out of stock

    £999.99

  • Imaging Gliomas After Treatment: A Case-based

    Springer Nature Switzerland AG Imaging Gliomas After Treatment: A Case-based

    Out of stock

    Book SynopsisThis book illustrates the characteristics of imaging after treatment in brain gliomas. It describes in detail the modifications to brain tissue, both healthy and pathological, that can manifest after surgery, radiotherapy or chemotherapy treatment. These modifications are discussed in terms of both how they occur in the immediate post-treatment period, and in the long term. The imaging methods used include CT with and without the addition of contrast medium, but above all MRI, which involves the use of routine basic sequences and mainly advanced study techniques such as diffusion, perfusion, spectroscopy and cortical activation. The aim of the text is to equip neuroradiologists with adequate expertise in post-treatment examinations reporting, allowing them to perform an effective differential diagnosis between the persistency or recurrence of illness and the effects of short or long-term treatment.The book is divided into a general section, which addresses the classification of cerebral tumors, the surgical treatment options, radiotherapy and chemotherapy protocols; and a section on clinical cases that employs rich iconography, making it quick and easy to consult. This second edition has been updated to reflect the new WHO classification system from 2016; new surgical, radiotherapy and chemotherapeutic treatment options; and (in the iconography section) the new sequences available from the manufacturers of RM scanners.Table of Contents

    Out of stock

    £999.99

  • Exercise Oncology: Prescribing Physical Activity

    Springer Nature Switzerland AG Exercise Oncology: Prescribing Physical Activity

    Out of stock

    Book SynopsisThis groundbreaking book presents a unique and practical approach to the evolving field of exercise oncology - the study of physical activity in the context of cancer prevention and control. Presenting the current state of the art, the book is sensibly divided into four thematic sections. Following an opening chapter presenting an overview and timeline of exercise oncology, the chapters comprising part I discuss primary cancer prevention, physical activity and survivorship, and the mechanisms by which these operate. Diagnosis and treatment considerations are discussed in part II, including prehabilitation, exercise during surgical recovery, infusion and radiation therapies, and treatment efficacy. Post-treatment and end-of-life care are covered in part III, including cardio-oncology, energetics and palliative care. Part IV presents behavioral, logistical and policy-making considerations, highlighting a multidisciplinary approach to exercise oncology as well as practical matters such as reimbursement and economics.Written and edited by experts in the field, Exercise Oncology will be a go-to practical resource for sports medicine clinicians, family and primary care physicians, oncologists, physical therapy and rehabilitation specialists, and all medical professionals who treat cancer patients.Table of ContentsChapter 1. Exercise Oncology: Past and Present Kathryn H. SchmitzPart 1 - Physical Activity and Cancer Prevention Chapter 2. Primary PreventionErika Rees-Punia, Alpa V. Patel Chapter 3. Physical Activity and Cancer SurvivalChristine M. Friedenreich, Chelsea R. Stone, Sandra C. Hayes Chapter 4. Mechanisms of Exercise in Cancer Prevention, Treatment and SurvivorshipHannah Savage, Keri L. Schadler Part 2 - From Diagnosis through TreatmentChapter 5. Exercise Oncology from Diagnosis through Treatment: An Overview of Outcomes and ConsiderationsCiaran M. Fairman, Daniel A. GalvãoChapter 6. Prehabilitation: An Emerging Standard in Exercise OncologyNicole L. Stout, Julie K Silver, Jennifer Baima, Sasha E. Knowlton, Xiaorong HuChapter 7. Exercise during Surgical Recovery Rosa M. Pasculli, Jonas Sokolof, Elizabeth Olecki, Kelly Stahl, Niraj GusaniChapter 8. Exercise during Infusion TherapyKristin L. Campbell, Amy KirkhamChapter 9. Exercise During Radiation TherapyJoachim WiskemannChapter 10. Effects of Exercise on Cancer Treatment Completion and EfficacyAndria R. Morielli, Kerry S. Courneya Part 3 – Post-treatment to End of LifeChapter 11. Exercise Oncology from Post-Treatment to End of Life: An Overview of Outcomes and ConsiderationsKira Bloomquist, Sandra C. Hayes Chapter 12. Exercise during Immediate Post-treatment Kerri Winters-Stone, Mary Medysky, Anna L. SchwartzChapter 13. Long-term and Late Effects of Cancer Treatments on Prescribing Physical ActivityAnna L. Schwartz, Jennifer W. Bea, Kerri Winters-StoneChapter 14. Exercise and Cardio-OncologyAmy M. Berkman, Susan C. Gilchrist Chapter 15. Energetics and Cancer OutcomesLeah M. Ferrucci, Melinda L. IrwinChapter 16. Exercise for Advanced Cancers, Metastatic Disease and Palliative CareSonya Lowe, Christopher Sellar, Kirsten Suderman, Margaret L. McNeely Part 4 - Behavior, logistics, and policyChapter 17. Cancer Survivors Becoming and Staying Physically Active: Challenges of Behavior ChangeBernardine M. Pinto, Madison M. Kindred, Chloe GrimmettChapter 18. Making Exercise Standard in Cancer Care Karen Basen-Engquist, Nathan H. ParkerChapter 19. Viewing Exercise Oncology through the Lens of MultidisciplinarityMartijn M. StuiverChapter 20. Policy and Reimbursement Considerations for Exercise Programming in CancerAndrea Cheville, Jennifer Baima, Philip Chang, Charles Mitchell, Stephanie Otto, Sonal Oza, David S. ZuckerChapter 21. Shaping the Future of Exercise OncologyKathryn H. Schmitz

    Out of stock

    £999.99

  • Practical Medical Oncology Textbook

    Springer Nature Switzerland AG Practical Medical Oncology Textbook

    Out of stock

    Book SynopsisThis textbook combines essential information on clinical cancer medicine with a guide to the latest advances in molecular oncology and tumor biology. Providing a systematic overview of all types of solid tumors, including epidemiology and cancer prevention, genetic aspects of hereditary cancers, differential diagnosis, typical signs and symptoms, diagnostic strategies and staging, and treatment modalities, it also discusses new and innovative cancer treatments, particularly targeted therapy and immunotherapy. Expert commentaries at the end of each chapter highlight key points, offer insights, suggest further reading and discuss clinical application using case descriptions. This textbook is an invaluable, practice-oriented tool for medical students just beginning their clinical oncology studies, as well as for medical oncology residents and young professionals.Trade Review“This book is best suited for an audience of senior medical residents, hematology/oncology fellows, advanced practice clinicians, and junior faculty. … a thorough reference to learners early in their careers.” (George M Rodgers, Doody's Book Reviews, February 25, 2022)Table of ContentsEpidemiology and Cancer Prevention.- Tumor biology and natural history.- Histopathology of the Tumors.- Biomarkers.- Liquid biopsy.- Diagnosis and staging.- Molecular Diagnostics: innovative technologies for clinical and translational research.- Hereditary cancers and genetics.- Principles of anti-cancer therapy: Chemotherapy.- Principles of anti-cancer therapy: Hormonal therapy.- Principles of anti-cancer therapy: Target Therapy.- Principles of anti-cancer therapy: Immunotherapy.- The role of Surgery.- Surgery in the Management of Gastrointestinal Stromal Tumors.- Integrated Treatments: The role of radiotherapy.- Response assessment to cancer therapy.- Clinical trials and methodology in cancer research.- Basic principles of bioinformatics for next generation sequencing molecular testing in oncology.- New drugs development.- Treatment toxicity.- Cardioncology.- The cancer cachexia.- Support and palliative care.- Physician-Patient Communication.- Breast Cancer: Locoregional and locally advanced disease.- Metastatic breast cancer.- Chest Tumors: Lung Cancer.- Malignant Pleural Mesothelioma.- Gastrointestinal Cancers: Oesophagus.- Gastric cancer.- Gastrointestinal Cancers: Stomach, advanced/metastatic disease.- Gastrointestinal Cancers: Colorectum, locoregional disease.- Metastatic colorectal cancer.- Anal Carcinoma.- Gastrointestinal Cancers: exocrine pancreas.- Gastrointestinal Cancers - Biliary cancer.- Hepatocellular Carcinoma.- Head and Neck Cancers (HNCs).- Central Nervous System Malignancies.- Genitourinary cancers: Kidney.- Bladder Cancer.- Genitourinary cancers: Prostate, locoregional disease.- Advanced and Metastatic Prostate Cancer.- Genitourinary cancers: Testis.- Genitourinary cancers: Penis.- Gynaecological cancers: Ovaris, early primary disease.- Gynaecological cancers: Ovaris, primary advanced and recurrent disease.- Gynaecological cancers: Uterus, endometrial and cervical cancer.- Vulvar and Vaginal Cancer.- Endocrine cancers: Adrenal gland.- Endocrine cancers: Thyroid.- Neuroendocrine Tumors.- Cutaneous Melanoma and other skin cancers.- Soft Tissue Sarcomas (STS).- The Role of Medical Treatment in the management of Gastrointestinal Stromal Tumors (GIST).- Bone health in cancer patients.- Nutrition and cancer.- Personalized medicine.- Categorization of Cancer Survivors.- Precision medicine in oncology: glossary of relevant scientific terms.

    Out of stock

    £999.99

  • Rheumatic Diseases and Syndromes Induced by

    Springer Nature Switzerland AG Rheumatic Diseases and Syndromes Induced by

    Out of stock

    Book SynopsisWith the increasing use of immune checkpoint inhibitors (ICI) across various cancers, the trends for indication at earlier stages, and the use of combination immunotherapy, the frequency of ICI-induced immune-related adverse events (irAE) is expected to grow substantially. Management of these irAE is challenging as it requires not only consideration of the toxicity but also risk-benefit ratios with respect to the primary cancer. Several rheumatic irAE have been reported with ICI therapy including arthritis, myositis, polymyalgia-like syndromes, sicca/Sjogren-like manifestations, and several other less common systemic autoimmune features commonly associated with connective tissue disease. This handbook provides clinicians with a comprehensive overview of the management of rheumatic irAE that develop from cancer immunotherapy. It focuses on the irAE seen with ICI, the most frequently used agents in treating cancer. It provides an overview of cancer immunology, immunotoxicity, and immunotherapies such as ICI, cytokine-based therapy, and CART. It examines the epidemiology, clinical manifestations, diagnosis, differential diagnosis, and treatment of a variety of rheumatic immune-related adverse events arising from these therapies. Chapters also cover cancer immunotherapy in patients with preexisting rheumatic diseases such as inflammatory arthritis and other connective tissue disorders. The book helps clinicians to distinguish the current types of cancer immunotherapy and general toxicity patterns, recognize and diagnose rheumatic clinical syndromes, understand the pathogenesis of irAE, and consider risk–benefit ratios when managing patients with rheumatic irAE.Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy is an essential resource for physicians and related professionals, residents, fellows, graduate students and nurses alike in rheumatology, clinical immunology, oncology, and internal medicine.Table of ContentsPART 1 - INTRODUCTION1. Cancer Immunology and the evolution of immunotherapy 2. Cancer immunotherapy: overview 3. Pathogenesis of immune-related adverse eventsPART 2 – IMMUNE-RELATED ADVERSE EVENTS WITH IMMUNE-CHECKPOINT INHIBITORS4. Arthritis 5. Polymyalgia rheumatica6. Myositis7. Sicca syndromes 8. Sarcoidosis 9. Miscellaneous rheumatic syndromes 10. Non-rheumatic immune-related adverse events11. Immune-related adverse events with other cancerimmunotherapiesPART 3 – CANCER IMMUNOTHERAPY IN PATIENTS WITH PRE-EXISTING RHEUMATIC DISEASES12. Inflammatory arthritis13. Other rheumatic autoimmune diseases14. Choosing the right therapy15. Risk-benefit considerations16. Patient education and shared-decision making

    Out of stock

    £999.99

  • Epigenetics and Proteomics of Leukemia: A Synergy

    Springer Nature Switzerland AG Epigenetics and Proteomics of Leukemia: A Synergy

    Out of stock

    Book SynopsisThis book reviews the current state of epigenetics and proteomics of leukemia and introduces the methods that are important to process and evaluate these factors in leukemia. In particular, epigenetic modifiers and their inhibitors in leukemia treatment as well as approaches to the epigenetic treatment of leukemia are covered. Various computational methods for proteome analysis are also described in detail, including 2DE fractionation and visualization, proteomic data processing, image acquisition and data anlaysis, and more. Protein localization in leukemia is also covered, in addition to the future of leukemia therapy. Epigenetics and Proteomics of Leukemia is an ideal book for advanced biomedical scientists and students, medical doctors and students, bioinformatics and health informatics researchers, computational biologists, structural biologists, systems biologists, and bioengineers.Table of ContentsOverview / IntroductionSection I: Epigenetics in Leukemia Chapter 1: Genetic and Epigenetic Alterations in Leukemia Chapter 2: Epigenetic Modifiers and Their Inhibitors in Leukemia Treatment Chapter 3: Chromatin Remodeling during Leukemia Cell Proliferation and Differentiation DNA Methylation and Epigenetic Regulation Chromatin Functional Regulation by Histone Modification Chapter 4: Approaches to Epigenetic Treatment of LeukemiaSection II: Proteomics in Leukemia Chapter 5: Proteome in Leukemic vs. Differentiated Leukemia Cells Chapter 6: Protein Phosphorylation in Leukemia Chapter 7: Computational Methods for Proteome Analysis 2DE Fractionation and Visualization Proteomic Data Processing Proteomic Data Analysis Image Acquisition and Data AnalysisSection III: Protein Localization in Leukemia Chapter 8: Protein Translocation into the Nucleus during Leukemia Cell Differentiation Chapter 9: Protein Visualization in Leukemic Cells Chapter 10: Computational Methods for Protein Localization Estimation Fluorescent Image Processing Fluorescent Image Acquisition and AnalysisSection IV: Future Therapy in Leukemia

    Out of stock

    £999.99

  • Tumor Suppressor Par-4: Structural Features,

    Springer Nature Switzerland AG Tumor Suppressor Par-4: Structural Features,

    Out of stock

    Book SynopsisPar-4 is a tumor suppressor protein first discovered and identified in 1993 by Dr. Vivek Rangnekar’s laboratory in prostate cancer cells undergoing apoptosis. Par-4 (later also known as PAWR) is a naturally occurring tumor suppressor. Studies have indicated that Par-4 selectively induces apoptosis in cancer cells while leaving normal, healthy, cells unaffected. Mechanisms contributing to the cancer-selective action of Par-4 have been associated with protein kinase A activation of intracellular Par-4 in cancer cells or GRP78 expression primarily on the surface of cancer cells. Par-4 is downregulated, inactivated or mutated in diverse cancers. This first of two volumes will be the first on the market on the topic of Par-4, and will provide the opportunity for researchers to discuss the future direction of studies, broaden the scope of research, and contribute a more complete understanding of the molecule’s structural features, key functional domains, regulation and relevant basic and clinical/translational facets.Table of ContentsIntroductionChapter 1. Discovery and Overview of Par-4Chapter 2. Significance of Par-4 Interaction with aPKCChapter 3. Structural Analysis of the C-terminal domain of Par-4Chapter 4. Crystallization and crystallographic analysis of the C-terminal domain of Par-4 (PAWR)Chapter 5. Role of ubiquitinase FBX045 in Par-4 regulationChapter 6. Regulation of Par-4 by type II phosphatidylinositol 4-kinase βChapter 7. Role of Par-4 in regulation of cell death by circumin and ceramideChapter 8. Par-4 in dissociation induced cell death in human pluripotent stem cellsChapter 9. Role of Par-4 in EMTChapter 10. Bacillus thuringiensis Induced Par-4 and Apoptosis in Human CellsChapter 11. Role of Par-4 in ZebrafishChapter 12. Role of Par-4 in GRP78 translocationChapter 13. Interaction of THAP1 with Par-4 in PML bodiesChapter 14. Regulation of DAPK and AMIDA by Par-4Chapter 15. Regulation of Par-4 by CK2 kinase

    Out of stock

    £999.99

  • Chondrosarcoma: Biology and Clinical Management

    Springer Nature Switzerland AG Chondrosarcoma: Biology and Clinical Management

    Out of stock

    Book SynopsisChondrosarcoma, a rare cancer that develops from cartilage cells, occurs mainly in the bones but can also appear in the soft tissue of the pelvis, hip and shoulder. Unfortunately, these cancers are highly resistant to both chemotherapy and radiation, and no successful adjuvant therapies currently exist. As such, surgical treatment and resection remain the mainstays of management for patients with these tumors. This concise text is a comprehensive presentation of the current knowledge regarding the development, diagnosis and management of chondrosarcomas. Part I discusses pathology, molecular biology and imaging features of chondrosarcomas. The different types of skeletal and extraskeletal tumors are presented in detail in part II, including conventional and secondary tumors. Management approaches are outlined and described in part III - limb salvage surgery is the most common, and although less effective, radiation and chemotherapy are indicated in certain cases. Part IV examines the future of chondrosarcoma management and development of novel adjuvant therapies, as well as the relationship of this disease to similar types (e.g., chordoma). Bringing together the most up-to-date information on this rare cancer, Chondrosarcoma will be a valuable resource for orthopedic oncologists, researchers and all medical professionals treating these challenging tumors. Table of ContentsPart I Biology of Chondrosarcoma 1 Pathology of Chondrosarcoma 2 Advances in the Molecular Biology of Chondrosarcoma 3 Imaging Features of Chondrosarcoma Part II 4 Chondrosarcomas: Conventional and Secondary 5 Primary Soft Tissue Chondrosarcoma Part III Management of Chondrosarcoma 6 Chondrosarcoma of the Axial Skeleton 7 Chondrosarcoma of the Appendicular Skeleton 8 Chondrosarcoma of the Hand 9 Chondrosarcoma of the Clavicle 10 Radiation Therapy for Chondrosarcoma 11 Systemic Therapy for Chondrosarcoma 12 Vascular Issues in Complex Surgical Resection of Chondrosarcoma Part IV The Future of Chondrosarcoma Research and Treatment 13 The Future of Chondrosarcoma Research and Treatment

    Out of stock

    £999.99

  • Chordoma of the Spine: A Comprehensive Review

    Springer Nature Switzerland AG Chordoma of the Spine: A Comprehensive Review

    Out of stock

    Book SynopsisThis book provides a comprehensive review of the epidemiology, pathogenesis, diagnosis, and management of chordomas of the mobile spine and sacrum. Historically, knowledge about how to deliver such state-of-the-art care has not been widespread, resulting in inconsistent treatment, and, all too often, suboptimal outcomes for chordoma patients. This text is an important step towards broadening that knowledge, and, in turn, improving the care provided to chordoma patients. The book is divided into 4 parts comprising 16 chapters. The first part focuses on the pathophysiology and molecular drivers of chordoma. The second focuses on the epidemiology and clinical history, as well as the histological, oncologic, and radiographic work-up of chordoma. The third part focuses primarily on the technical aspects of surgery for chordoma. It is broken down by anatomic region, with the final two chapters focusing on the soft tissue and bony reconstruction following chordoma resection. The last part focuses on the exciting field of adjuvant therapies for chordoma. This includes both radiation therapies and novel chemotherapeutic options for recurrent, metastatic, and dedifferentiated chordoma. Written by world experts from leading chordoma centers, Chordoma of the Spine serves as a valuable reference for spinal oncologists and general spine surgeons who may encounter chordoma patients in their practice. It provides the most up-to-date evidence regarding all aspects of treating patients with this disease. By focusing on this specific pathology of the spine, this resource condenses expert-level research into understandable treatment algorithms.Table of ContentsSection I Pathophysiology and Molecular Mechanisms of Chordoma1 Notochordal Morphogenesis and the Origin of Chordoma Matthew L. Goodwin, MD PhD, David C. Clever, MD PhD2 Molecular and Genetic Mechanisms of Spinal ChordomaConnor Liu, BS; Ann Liu, MD; Chetan Bettegowda, MD/PhDSection II Epidemiology, Clinical History, and Work-Up for Chordoma3 Historical Overview, Demographics, and Clinical Presentation of Spinal Chordoma Zach Pennington BS, Andrew Schilling AB, Joseph H. Schwab MS MS, Daniel M. Sciubba MD4 Clinical Work up, Diagnostic Imaging and Biopsy Daniel Ryan, MD; John Gross, MD; Zach Pennington BS, Majid Khan, MD5 Histopathologic Classification of Spinal Chordoma John M Gross MD, Edward F McCarthy MD6 Multi-disciplinary Planning for Treatment Nicholas A Shepard MD, Matthew W Colman MDSection III Surgical Management of Chordoma7 Surgical Management of Chordoma of the Occipitocervical Junction Zach Pennington BS, Jeff Ehresman BS, Andrew Schilling BA, Daniel M. Sciubba MD8 Surgical Management of Chordoma of the Cervical Spine Oliver G.S. Ayling MD, MSc, Nicolas Dea MD, MSc9 Surgical Management of Chordoma of the Thoracic Spine Daniel G. Tobert MD, John H. Shin MD, Joseph H. Schwab MD10 Surgical Management of Chordoma of the Lumbar Spine Sutipat Pairojboriboon MD, Amanda Sacino MDPhD, Sheng-fu Larry Lo MD11 Surgical Management of Chordoma of the Sacrum Peter S. Rose, MD, Matthew T. Houdek, MD, Cory G. Couch, MD12 Soft Tissue Reconstruction Following Surgery for Sacral Chordoma Rachel Skladman MD, Zach Pennington BS, Justin M. Sacks MD MBA FACS13 Vascular Reconstruction After EnBloc Resection. Daniel G. Tobert MD, Joseph H. Schwab MDSection IV Radiation and Chemotherapeutic Adjuvants for Chordoma14 Photon Therapy for Chordoma of the Spine Chunzi Jenny Jin MD MSc, Yoshiya Josh Yamada MD FRCPC15 Heavy Particle Therapy for Chordoma David J. Konieczkowski MD PhD, Reiko Imai MD, Thomas F. DeLaney MD16 Systemic Therapy, Trials and Future Directions for Chordoma of the Spine Daniel J. Zabransky, MD, PhD, Zach Pennington BS, Christian Meyer, MD, MS, PhDIndex

    Out of stock

    £999.99

  • Uveal Melanoma: Biology and Management

    Springer Nature Switzerland AG Uveal Melanoma: Biology and Management

    1 in stock

    Book SynopsisThis book provides a comprehensive examination of uveal melanoma, a rare neoplasm that carries a very high mortality and whose natural history makes it fairly unique among adult tumors. Split into three sections, this book explores the basic science behind the disease and inherited genetic syndromes that predispose some patients, as well as the pathology and use of gene expression profiling to determine risk of recurrence. It also focuses on the management of the primary tumor in the eye, including surgical intervention and lesion imaging. Elucidating treatment options for metastatic disease, the book reviews chemotherapy agents and immunotherapy approaches, as well as liver-directed therapies, cellular therapies, and various treatments after primary treatment but before the development of metastases.Uveal Melanoma: Biology and Management is the most up-to-date and comprehensive text devoted solely to this disease and will be useful to medical oncologists, ophthalmologists, radiation therapists, interventional radiologists, pathologists, molecular biologists and immunology researchers, as well as trainees in those fields.Table of ContentsMolecular Basis of Uveal Melanoma and Emerging Therapeutic Targets.- Clinical/Commercial.- Genetic Testing in UM.- BAP1 Tumor Predisposition Syndrome.- Pathology of Uveal Melanoma.- Epidemiology of Uveal Melanoma and Potential Clusters.- Gene Expression Profiling in the Management of Uveal Melanoma.- Surgical Considerations of Radiation Plaques and Enucleation.- Uveal Melanoma: Imaging.- Radiation Therapy in Ocular Melanoma.- Late Complications of Radiation Therapy in Uveal Melanoma.- Nanoparticles for the Treatment of Uveal Melanoma.- Screening Schedules for Metastatic Disease.- Adjuvant Therapy of Uveal Melanoma Liver-Directed Therapies for Hepatic Metastases.- Systemic Therapy for Metastatic Uveal Melanoma.- Cell Therapy for Uveal Melanoma.

    1 in stock

    £61.74

  • Immunotherapy

    Springer Nature Switzerland AG Immunotherapy

    Out of stock

    Book SynopsisThe field of immuno-oncology continues to rapidly evolve as new insights to fight and treat cancer emerge. The fourth edition of Immunotherapy provides the most current overview of immuno-oncology in different cancer types and toxicities associated with immunotherapy. While immunotherapy has revolutionized the treatment landscape of several solid malignancies, several challenges still exist.Only a subset of patients derive clinical benefits; some do not respond at all, and others respond initially, only for their disease to progress later. Because these drugs can activate a broad range of immune cells, patients suffer from a unique set of side effects known as immune-related adverse events. As more immunotherapeutic agents are used in the clinic, it is important to provide updates about current and ongoing developments in the field to further research efforts and inform treatment decisions.The fourth edition will have a new focus on strategies to overcome the challenges associated with immunotherapy. Chapters will discuss topics such as biomarkers of response, resistance mechanisms, role of imaging in predicting immune-related adverse events, and management of immune-related adverse events. Written by leading experts conducting cutting-edge research, readers will gain up-to-date knowledge on the current state and future of immunotherapy. Table of ContentsTable of contents1. Immune System in Action2. Resistance to Immunotherapy: Mechanisms and Means for Overcoming3. Immunotherapy for Melanoma4. Immunotherapy in Lung Cancer: Are the promises of long-term benefit finally met?5. Landscape of Immunotherapy in Genitourinary Malignancies6. Immuno-oncology for Gynecologic Malignancies7. Immunotherapy for Neuro-oncology8. Immunotherapy in Gastrointestinal Malignancies9. An update on immune based therapies in acute myeloid leukemia: 2021 and beyond!10. CAR T-cells11. Skin Reactions to Immune Checkpoint Inhibitors12. Immunotherapy Mediated luminal Gastrointestinal toxicities13. Hepatobiliary and Pancreatic Adverse Events 14. Pulmonary toxicities of immunotherapy 15. Immune checkpoint inhibitors (ICIs) related cardiotoxicity16. Renal Toxicity17. Immune-Related Oral, Otologic and Ocular Adverse Events18. Neurologic Toxicities of Immunotherapy19. Cancer Imaging in Immunotherapy

    Out of stock

    £999.99

  • Tumor Suppressor Par-4: Role in Cancer and Other

    Springer Nature Switzerland AG Tumor Suppressor Par-4: Role in Cancer and Other

    Out of stock

    Book SynopsisPar-4 is a naturally occurring tumor suppressor. Studies have indicated that overexpression of Par-4 selectively induces apoptosis in cancer cells while leaving normal, health, cells unaffected. Mechanisms contributing to this cancer-selective action of Par-4 have been associated with PKA activation of intracellular Par-4 in cancer cells or GRP78 expression primarily on the surface of cancer cells. On the other hand, endogenous Par-4 sensitizes cells to the action of a broad range of apoptotic inducers acting via the extrinsic and intrinsic pathways. A number of binding partners of Par-4 have been identified and shown to regulate Par-4 function in cancer and other diseases, such as Alzheimer’s and major depression. Recent studies have recognized a number of natural products, dietary supplements, synthetic molecules and FDA-approved drugs that induce the secretion of Par-4 protein to cause apoptosis in primary or metastatic tumors, one of which is in clinical trials. More than 50 different laboratories worldwide are involved in Par-4 based research of this unique protein that has progressed from the bench to clinical trials. This second, companion volume will provide a comprehensive overview of Par-4’s role in cancer and other diseases. Chapters are written by leading researchers, and will be useful for a broad audience across the scientific community, particularly students and trainees, who are the next generation of scientists and clinicians to participate in new studies and discoveries on Par-4.Table of ContentsIntroductionPart 1Chapter 1. Role of Par-4 in lung cancerChapter 2. Prostate apoptosis response-4 in nasopharyngeal carcinomaChapter 3. Role of Par-4 in Chemoresistance and targeted therapies in ovarian and endometrial cancersChapter 4. Regulation of Par-4 and role in GI tumorsChapter 5. Role of Par-4 in prostate cancerChapter 6. Activation of apoptosis by Par-4 in pancreatic cancerChapter 7. Role of Par-4 and GRP78 in GlioblastomaChapter 8. Role of Par-4 in breast cancer recurrenceChapter 9. Involvement of Par-4 in breast cancerChapter 10. Role of endogenous Par-4 in CLLChapter 11. Role of Par-4 in inhibition of TCL1 induced growthChapter 12. Par-4/THAP in survival of T-cell acute lympoblastic leukemia cellsChapter 13. Par-4 expression in cholangiocarcinomaChapter 14. Par-4 suppresses breast cancer growth and invasion of breast cancer cellsChapter 15. PAWR as direct SRC-1/HOXC11 suppression targetChapter 16. Par-4 cleavage is required for TNF induced apoptosisChapter 17. Par-4 secretagoguesChapter 18. Recombinant production and characterization of SACChapter 19. Anti-tumor effects of plant derived Par-4Chapter 20. Par-4 in Mycobacterium tuberculosis Infected MacrophagesPart 2 - Role in other DiseasesChapter 21. Role of Par-4 in ceramide inducible effects in neuronsChapter 22. Role of Par-4 in Alzheimers diseaseChapter 23. Dopamine signaling in association with induction of Par-4 protein expressionChapter 24. Par-4 (PAWR) in major depressive disorderChapter 25. Par-4 dependent apoptosis of islet β cells in type 2 diabetesChapter 26. Par-4 in cardiac fibroblast senescenceChapter 27. Par-4 in ocular development and diseaseChapter 28. Par-4 in apoptosis during human salivary gland developmentChapter 29. Suppression of Par-4 protects human renal proximal tubule cells from apoptosisChapter 30. Lessons from knockout micePart 3 - From Bench to BedsideChapter 31. Par-4 secretagogues in clinical trialsChapter 32. Potential of Par-4 as a therapeutic target for cancer

    Out of stock

    £999.99

  • Transradial Access in Interventional Radiology:

    Springer Nature Switzerland AG Transradial Access in Interventional Radiology:

    Out of stock

    Book SynopsisThis book provides how-to recommendations and detailed guides for using transradial access in interventional radiology. A relatively new and growing technique, transradial access is most commonly found within interventional cardiology. This book approaches those cardiac uses of transradial access while extending its use to other body sites and disease states. The book details the interventional radiologist’s transition to using transradial access across a broad spectrum of clinical applications, allowing them to better introduce it into their practice and to their patients. The text is divided into three sections: overview, clinical applications, and novel applications and techniques. The first section covers the history of transradial access, the initial patient assessment, and how to prepare for a procedure. The second section is divided into different diseases and interventional situations where transradial access could be considered, including subclavian artery stenosis and endovascular neurosurgery. The third section includes coverage of how to perform the latest techniques and projections for future procedures. This guide provides a manual of operations to assist in the setup of the practice, from office visit to procedure room to recovery across a variety of service lines and patient populations. Key take home points and equipment summaries accompany each chapter, allowing the user to easily navigate the book to accelerate his or her practice. This is an ideal guide for interventional radiologists. Table of ContentsTransradial Access in Interventional Radiology: Background, Applications and Techniques 1. The Advent of Transradial Interventions: An Overview 2. Anatomy and Physical Exam 3. Nursing Assessment 4. Procedure Suite Set-Up 5. Recovery Room and Post Procedure Care 6. Access Complications and Management 7. Transradial Access for Renal and Mesenteric Artery Disease 8. Transradial Access for Interventional Oncology: Chemoembolization and Radioembolization Applications 9. Transradial Access for Peripheral Arterial Disease: Aortoiliac Applications 10. Transradial Access for Peripheral Arterial Disease: Infrainguinal Applications 11. Aortic Endoleak following Endovascular Aortic Repair 12. Transradial Access for Peripheral Arterial Disease: Subclavian and Upper Arm Interventions 13. Transradial Access in Uterine Artery Embolization 14. Prostate Artery Embolization 15. Hemodialysis Access Interventions 16. Carotid and Vertebral Intervention 17. Endovascular Neurosurgery and Stroke Intervention 18. Acute Hemorrhage and Trauma 19. Transulnar Arterial Access 20. Distal Transradial Arterial Access 21. Transradial Access for Bariatric Embolization

    Out of stock

    £999.99

  • Tumor Microenvironment: Cellular, Metabolic and

    Springer Nature Switzerland AG Tumor Microenvironment: Cellular, Metabolic and

    Out of stock

    Book SynopsisOver the past decade, the tumor microenvironment has become one of the most important research areas in cancer biology, as cells within the tumor microenvironment, despite being outnumbered by healthy cells, are able to evade surveillance and immune-mediated destruction. While researchers have learned a great deal about the cellular and structural makeup of the tumor microenvironment, there has been a growing understanding of the metabolic interplay between the tumor micronenvironment’s various cellular constituents and how each of them contributes to overall tumor growth and metastases. This new volume will guide researchers, students, oncologists and academics through a rapidly developing and changing field with a thorough understanding of tumor microenvironment biology from a cellular, structural, metabolic, and immunological perspective.Table of Contents1. Inflammatory components of the thyroid cancer microenvironment - an avenue for identification of novel biomarkers2. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity3. Exosomes in the Healthy and Malignant Bone Marrow Microenvironment4. Structural Biology of the Tumor Microenvironment5. Metabolic interactions between tumor and stromal cells in the Tumor Microenvironment6. Interacting Genetic Lesions of Melanoma in the Tumor Microenvironment: Defining a Viable Therapy7. Non-coding RNAs in Papillary Thyroid Cancer: Interaction with cancer associated fibroblasts (CAFs) in the Tumor Microenvironment (TME) and regulators of differentiation and Lymph Node Metastasis

    Out of stock

    £999.99

  • Clinical Nuclear Medicine in Neurology: An Atlas

    Springer Nature Switzerland AG Clinical Nuclear Medicine in Neurology: An Atlas

    Out of stock

    Book SynopsisThis book gathers a collection of cases with challenging diagnoses, in which nuclear medicine examinations have been particularly helpful in terms of the final diagnosis or follow-up. The cases presented chiefly involve patients with neurodegenerative disorders, epilepsy and brain tumors. The book is intended for nuclear medicine specialists as well as clinicians, offering essential guidance on the interpretation of neurology cases in the clinical setting, particularly with regard to correctly interpreting diagnostic imaging procedures. The authors were selected from the members of the Neuroimaging Committee of the EANM and have extensive experience as clinicians and teachers within the Nuclear Medicine Community. Trade Review“The great interest of this book derives from the fact that, in 200 pages enriched by 100 figures, it analyzes a myriad of exemplary challenging cases in which diagnostic neuroimaging, based on optimized user-independent methods, allowed a correct final diagnosis. … I strongly suggest the acquisition of this publication not only to nuclear physicians and neuro-radiologists but also to all the professionals interested to better understand cerebral diseases. I believe that this book should be present in all the libraries of departments dealing with the brain.” (Luigi Mansi, European Journal of Nuclear Medicine and Molecular Imaging, January 13, 2022)Table of ContentsSECTION I - Nuclear Medicine cases of dementia and movement disorders.- Case 1: Mild cognitive impairment (MCI) – [18F]FDG and amyloid PET.- Case 2: Alzheimer´s disease - [18F]FDG, tau and amyloid PET.- Case 3: Alzheimer´s disease – Behavioural variant.- Case 4: Parkinson´s disease with onset as MCI.- Case 5: Parkinson´s disease with vascular abnormalities.- Case 6: Parkinson´s disease with left-side spasticity.- Case 7: Holmes tremor.- Case 8: Multiple system atrophy with DAT SPECT and [18F]FDG PET.- Case 9: Progressive supranuclear palsy: Richardson syndrome and Parkinsonian variants.- Case 10: Progressive supranuclear palsy.- Case 11: Corticobasal syndrome - [18F]FDG and amyloid PET.- Case 12: Huntington´s disease with atypical onset.- Case 13: Huntington´s disease with psychiatric onset.- Case 14: Creutzfeldt–Jakob disease with pathological confirmation.- SECTION II - Nuclear Medicine cases of epilepsy and encephalitis. Case 15: Temporal lobe epilepsy.- Case 16: Ictal imaging in partial status epilept cus.- Case 17: Focal pharmacoresistant epilepsy.- Case 18: Post-surgical epilepsy.- Case 19: Thalamic hamartoma.- Case 20: Autoimmune encephalitis with unusual antibodies.- Case 21: Psychiatric presentation of anti-N-methyl-D-aspartate receptor (NMDAR) limbic encephalitis.- Case 22: Hashimoto encephalitis. SECTION III - Nuclear Medicine cases of brain tumors.- Case 23: Pseudoresponse in a case of Glioblastoma multiforme.- Case 24: Progressive Glioma.- Case 25: Isocitrate dehydrogenase (IDH) wild-type glioma.- Case 26: Post-operative meningioma.- Case 27: Meningioma with difficult delineation on MRI.- Case 28: Optic nerve sheath meningioma (ONSM).- Case 29: Primary brain lymphoma.- Case 29: Neurolymphomatosis.- Case 30: Atypical teratoid rhabdoid tumor (ATRT).- Case 31: Brain metastatis – progression/recurrence vs. radionecrosis.- Case 32: Tumefactive plaques.- SECTION IV - PET/MRI and challenging cases.- Case 33: Typical AD with discordant biomarkers.- Case 34: Fronto-temporal dementia, behavioural variant, mimicker.- Case 35: Creutzfeldt–Jakob disease.- Case 36: Amyotrophic lateral sclerosis.- Case 37: Epilepsy.- Case 38: Limbic encephalitis.

    Out of stock

    £107.99

  • Smart Nanomaterials in Biomedical Applications

    Springer Nature Switzerland AG Smart Nanomaterials in Biomedical Applications

    Out of stock

    Book SynopsisWith the start of 2020, the wrath of pandemic challenged the scientific community to develop more advanced drug delivery approaches for biomedical applications, endowing conventional drugs with additional therapeutic benefits and minimum side effects. Although significant advancements have been done in the field of drug delivery, there is a need to focus towards strategizing novel and improved drug delivery systems that should be convenient and cost-effective to the patients, and simultaneously they should also provide financial benefits to pharmaceutical companies. Controlled drug delivery technology offers ample opportunities and scope for improvising the therapeutic efficacy of drugs via optimizing the drug release rate and time. For this endeavour, smart nanomaterials have served as remarkable candidates for biomedical applications, owing to their ground-breaking properties and design. The development of such nanomaterials requires a broad knowledge related to their physio-chemical properties, molecular structure, mechanisms by which the nanomaterials interact with the cells, and methods by which drugs are released at the site of action. This knowledge must also be allied with the knowledge of signaling crosstalk mechanisms that are modulated by the nanomaterial-drugs composite. It can be anticipated that these emerging drug delivery technologies can facilitate the world to successfully encounter such pandemic outbursts in the future in a cost-effective and time-effective manner. The chapters in this book deal with the advanced technologies and approaches that can benefit advanced students, researchers, and industry experts in developing smart and intelligent nanomaterials for future biomedical applications, and development, manufacturing, and commercialization for controlled and targeted drug delivery.Table of ContentsFOREWORDProf. G. VeerabhadramPREFACEChapter 1: Introduction to active smart nanomaterials for biomedical applicationsJin-Chul KimKangwon National University, Chuncheon, South Korea Chapter 2: Cancer cell sensing and therapy using affinity tag-conjugated gold nanoparticlesAlle MadhusudhanKangwon National University, Chuncheon, South Korea Chapter 3: Gold nanoparticles enlighten the future of cancer theranosticsJianfeng GuoSchool of Pharmaceutical Sciences, Jilin University, 1266, Fujin Road, Changchun 130021, ChinaChapter 4: Recent advances in hydrogels smart drug delivery systems Sharif AhmadDepartment of Pharmacology, All India Institute of Medical Sciences, India Chapter 5: Carbon-based nanomaterials for biomedical applicationsKai YangState Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, China Chapter 6: A new era of cancer treatment: carbon nanotubes as drug delivery toolsAlexander M SeifalianCentre for Nanotechnology and Regenerative Medicine, University, College London, London, UK Chapter 7: pH- and ion-sensitive materials for control drug delivery Takayuki YoshidaDrug Delivery, Pharmaceutical Research and Technology Labs, Astellas Pharma, Inc., 180 Ozumi, Yaizu, Shizuoka 425-0072, JapanChapter 8: Thermo-responsive polymers and their application as smart biomaterialsYukiko T. MatsunagaCenter for International Research on Integrative Biomedical Systems (CIBiS), The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8505, JapanChapter 9: Redox-responsive polymers and their application in drug delivery systemsJohn F. QuinnARC Centre of Excellence in Convergent Bio-Nano Science & Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Melbourne, Victoria 3052, AustraliaChapter 10: Recent strategies to explore the biomedical applications of nanocelluloseDinesh KumarKangwon National University, Chuncheon, South Korea Chapter 11: Tissue engineering using cellulose nanofibrils as Scaffold MaterialAndrew E. PellingSymbioticA, School of Human Sciences, University of Western Australia, Perth, WA, AustraliaChapter 12: Use of solid lipid nanoparticles to improve the oral bioavailability of poor soluble drugsDeepti PanditaDepartment of Pharmaceutics, Jan Nayak Ch. Devi Lal Memorial College of Pharmacy, Sirsa 125055, Haryana, IndiaChapter 13: Applications of dendrimers in drug delivery systemsE. BustosCentro de Investigacion y Desarrollo Tecnol ´ ogico en Electroqu ´ ´ımica S.C., Parque Tecnologico Quer ´ etaro s/n, Sanfandila, 76703 Pedro Escobedo, QRO, MexicoChapter 14: Liposomes for drug delivery: progress and problemsJin-Chul KimKangwon national University, Chuncheon, South KoreaChapter 15: Cubosome nanoparticles for enhanced delivery of anticancer drugJana B. NiederDepartment of Nanophotonics, Ultrafast Bio- and Nanophotonics Group, INL - International Iberian Nanotechnology Laboratory, Av. Mestre José Veiga s/n, 4715-330, Braga, PortugalChapter 16: Layer‐by‐Layer assemblies for cancer diagnosis and treatment UMR CNRS/INPG 5628 (LMGP), 3 parvis Louis Néel, 38016 Grenoble, FranceChapter 17: Polymeric micelles for drug deliveryAfsanesh Lavasanifar University of Albert, Edmonton, Alberta T6G2N8, CanadaChapter 18: Role of plant-based materials/gums in developing drug delivery systems B. Sashidhar Rao Department of Biochemistry, Osmania University, Hyderabad, IndiaChapter 19: Ethosomes: A novel tool for drug delivery through the skinAmarachinta Padmanabha RaoChapter 20: Niosomes as nanoparticular drug carriers: fundamentals and recent applicationsNoufel SamedChapter 21: Graphene oxide nanosheets used in photothermal therapyHongjie Dai Department of Chemistry, Stanford University, Stanford, California 94305, United States Chapter 22: Metal doped carbon dots used in bio-imaging and cancer therapyJoydeep DasSchool of Chemistry, Shoolini University of Biotechnology and Management Sciences, Bajhol, PO Sultanpur, Solan, HP, 173229, IndiaBIBLIOGRAPHYGLOSSARYINDEX

    Out of stock

    £999.99

  • Renal Cancer: Current Status and Innovations

    Springer Nature Switzerland AG Renal Cancer: Current Status and Innovations

    Out of stock

    Book SynopsisRenal Cancer: Current Status and Innovations provides a useful guide to the fundamental basics and latest diagnostic and treatment techniques for Renal Cancer. It features clearly structured and easy-to-understand chapters enabling the reader to develop a thorough understanding of screening, surveillance, diagnostics, pathology, robotic and open surgical approaches, ablation, medical treatment, psychology, and future innovations. The book provides a valuable resource for the full spectrum of clinicians involved in the multidisciplinary management of Renal Cancer.Table of ContentsIntroduction to the Multidisciplinary approach to Renal Cancer.- Imaging in Renal Cancer.- Application of Simulation Techniques.- Cognitive Simulation & Non technical skills training.- Team training.- Active surveillance and Percutaneous Treatment.- Endoscopic Surgery.- Laparoscopic Renal Surgery.- Robotic Surgery.- Focal Therapies.- Pre and Post-surgery, treatments.- Big Data and Renal Outcomes.- Future perspectives.

    Out of stock

    £999.99

  • Depression, Burnout and Suicide in Physicians:

    Springer Nature Switzerland AG Depression, Burnout and Suicide in Physicians:

    Out of stock

    Book SynopsisThis book provides a reference and contextual basis for depression, burnout and suicide among oncology and other medical professionals. Oncology as a medical subspecialty is at a unique apex of this crisis. While the same pressures in medicine certainly apply to oncologists, oncology is particularly stressful as a changing field with diverse patient and societal expectations for outcomes. In addition to experiencing the stress of caring for patients that could succumb to their cancer diagnoses, these professionals are regularly confronted with an onslaught of new medical information and a landscape that is changing at a breakneck pace. These are just a few factors involved in the increasing rates of burnout among oncologists as well as other medcial professionals. By addressing a gap in identifying mental health problems among health care professionals, this book sheds light on mental health problems and suicide among physicians. Importantly, this book is a call to action of the professional and administrative organizations to work on improving mental health of physicians. Anxiety and depression affect not only the individual doctor but also patient care. Given the increasing attention to these issues along with limited yet applicable data regarding how to address these issues, the text aims to bring the latest data face to face with consensus opinion and can be used to ultimately enhance oncologic and psychiatric practices. Written by experts in the field, Depression, Burnout and Suicide in Physicians: Insights from Oncology and Other Medical Professions aims to significantly increase awareness and contribute to understanding the necessity of preventive measures on individual, family, and care givers levels.Table of Contents1 The problem of Burnout, Depression, and Suicide in Physicians. A general overview 2 Medical Professionalism and Physician Dignity: Are we at risk of losing it? 3 Burnout in Medicine 4 Depression and substance use disorders in physicians. 5 Suicide and suicide risk in physicians 6 Screening and Assessment of Burnout With a Focus on Oncology Healthcare Providers 7 The Ethical Implications of Burnout: A Moral Imperative to Prioritize Physician Well-Being, Resilience, and Professional Fulfillment 8 Euthanasia and Medical Assistance in Dying as challenges for physicians’ well-being 9 Moral Distress in Physicians 10 Embitterment in the workplace 11 Prevention of burnout through resilience, wellness programs, and civility in the work environment 12 Cultivating Resilience and Preventing Burn Out: A Mindful Multi-Pronged Intervention Approach

    Out of stock

    £999.99

  • Psychological Aspects of Cancer: A Guide to

    Springer Nature Switzerland AG Psychological Aspects of Cancer: A Guide to

    Out of stock

    Book SynopsisThis book addresses the unmet needs of the medical community in dealing with the psychological problems, particularly anxiety and depression, of patients diagnosed with cancer. Providing a scholarly review of the impact of cancer diagnosis on patients’ emotional and psychological status, as well as the evidence that psychological factors impact cancer occurrence and biological behavior, this book explores the therapeutic implications of such converse dynamics. Chapters review financial toxicity, eHealth, palliative care, mindfulness, sleep and cancer, social support and cancer, cultural diversity, pediatric and adolescent oncology, and geriatric oncology. While intended primarily for the professional readership of oncologists, psychologists, psychiatrists, social workers, and palliative care physicians, a final chapter also provides practical information on available resources for patients. This fully updated and expanded new edition of Psychological Aspects of Cancer: A Guide to Emotional and Psychological Consequences of Cancer, Their Causes, and Their Management provides practitioners with cutting edge knowledge as well as practical information that translates into better care for patients with cancer. Table of ContentsInflammation, Chronic Disease, and Cancer: Is Psychological Distress the Common Thread?.- Psychological Factors and Survivorship: A Focus on Post-Treatment Cancer Survivors.- Couple Relationships and Cancer.- The Impact of Cancer and Its Therapies on Body Image and Sexuality.- Use of the Classic Hallucinogen Psilocybin for Treatment of Existential Distress Associated with Cancer.- Meaning, Spirituality, and Perceived Growth Across the Cancer Continuum: A Positive Psychology Perspective.- Stress, Coping, and Hope.- Religiousness and Spirituality in Coping with Cancer.- Psychoneuroimmunology and Cancer: Mechanisms Explaining Incidence, Progression, and Quality of Life Difficulties.- Psychosocial Interventions in Cancer.- Altruism in Relation to Live Donor Liver Transplants for Liver Cancer.- New and Emerging Challenges in Advanced Cancer Care: Opportunities for Enhancing Patient-Centered Communication.- Complementary Mind-Body Therapies in Cancer.- The Intersection between Cancer and Caregiver Survivorship.- Controversies in Psycho-Oncology.- Resources for Cancer Patients.- Adolescent and Young Adult Cancer Survivors.- Cancer Fatalism: Attitudes Toward Screening and Car.- The Intersection between Cancer and Caregiver Survivorship.- Cancer and the Aging Population.- Mindfulness Based Interventions for Patients with Cancer.- Social Genomics and Cancer: Neural Regulation of the Cancer Genome.- Psychological Aspects of Hereditary Cancer Risk Counseling and Genetic Testing: Toward an Expanded and More Equitable View.- Meaning-Centered Psychotherapy.- Quality of Life.- Bringing It All Together.

    Out of stock

    £999.99

  • Management of the Breast and Axilla in the

    Springer Nature Switzerland AG Management of the Breast and Axilla in the

    Out of stock

    Book SynopsisOver the last several decades breast cancer management has made great strides in the improvement of oncologic treatment outcomes, particularly so in patients with early stage disease. While wide-spread access to screening resulting in early detection is undoubtedly to be credited for this trend, at the same time, the management of breast cancer has evolved to be an intricate multidisciplinary collaboration between breast imagers, surgeons, medical oncologists and radiation oncologist. As a result, with better mutual understanding of multidisplinary goals and challenges, the treatment strategies have become more individualized, with a great emphasis being placed on the intrinsic disease biology. Furthermore, the indications for neoadjuvant systemic therapy have significantly broadened, with a substantial number of patients with early stage breast cancer being able to take advantage of this strategy to decrease the extent of breast surgery they would undergo at its completion. As such, the management of the axilla in these patients has presented with new challenges as well as with new opportunities to scale down on the extent of local therapy and, consequently, its toxicity.This text will provide a comprehensive, state-of-the art review of this field, and will serve as a valuable resource for clinicians (surgeons, medical oncologists, radiation oncologists) and researchers with an interest in breast cancer. The book will review novel and evoling strategies in neoadjuvant systemic therapy forn early stage breast cancer, provide new perspectives about appropriate axillary imaging in anticipation of neoadjuvant systemic therapy, and describe new data on innovative surgical techniques and Radiation Oncology concepts designed to deescalate the extent and toxicity of local therapy while insuring oncologic safety. Several landmark clinical trials have been published in the last few years and will be placed in context with respect to current management. Integration of novel diagnostic and interventional breast imaging, local therapy (surgery and radiation) with contemporary systemic therapy will also be discussed. This text will serve as a very useful resource for physicians and researchers dealing with, and interested in, this challenging field. It will provide a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts. All chapters will be written by experts in their fields and will include the most up to date scientific and clinical information.Table of ContentsEvolution of the indications for neoadjuvant systemic therapy.- Defining response.- Imaging of the breast.- Imaging of the axilla and approach to node-negative vs. node-positive disease at presentation.- Guidelines for imaging during neoadjuvant systemic therapy.- Neoadjuvant systemic therapy based on the underlying tumor biology.- Adjuvant vs. neoadjuvant systemic therapy.- Molecular testing and personalized neoadjuvant treatment.- Pre-and post-neoadjuvant systemic therapy imaging assessment.- Surgical management of the axilla in node-negative and node-positive disease at diagnosis.- Surgical considerations and expectations in patients receiving neoadjuvant hormonal therapy and neoadjuvant chemotherapy.- Postmastectomy radiation considerations in patients receiving neoadjuvant chemotherapy.- Pathologic evaluation in neoadjuvant systemic therapy setting.- Guidelines for Neoadjuvant systemic therapy.- Ongoing Clinical studies and future direction.

    Out of stock

    £999.99

© 2026 Book Curl

    • American Express
    • Apple Pay
    • Diners Club
    • Discover
    • Google Pay
    • Maestro
    • Mastercard
    • PayPal
    • Shop Pay
    • Union Pay
    • Visa

    Login

    Forgot your password?

    Don't have an account yet?
    Create account